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Title: Examination of allergenic properties of recombinant banana 
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Abstract 
Food allergy is defined as an adverse health effect arising from a specific immune response 
that occurs reproducibly on exposure to a given food. Currently, food allergy is a major 
health problem, with an estimated prevalence of about 5% in young children and 3-4% in 
adults, and the prevalence is increasing. Food allergies present a challenge in the field of 
diagnostics, since the currently employed allergen extracts frequently give rise to poor 
specificity and sensitivity of tests. Recombinant DNA technology developed in the 1980s 
has provided the means for producing allergens that are equivalent to their natural 
counterparts. The proteins are produced as biochemically defined molecules with consistent 
structural and immunologic properties. Several hundred allergens have been cloned and 
expressed as recombinant proteins, and they can provide the means for making a very 
detailed diagnosis of a patient's sensitization profile. The production of recombinant 
proteins in a well-characterized form has become an important issue in the pharmaceutical 
industry. 
Banana (Musa acuminata) is a very popular fruit worldwide. It is available year round and 
is very present in human nutrition. However, in 1991 symptoms of allergic reaction to 
banana were described for the first time. The molecular basis of allergic reactions to banana 
has been ascribed to five proteins, designated Mus a 1 to 5. The Mus a 5 allergen is a β-1, 
3-glucanase belonging to the PR-2 family of proteins and is involved not only in plant 
defense, but also in diverse physiological and developmental processes. 
 
In this thesis banana β-1,3-glucanase was produced as a heterologous protein in 
Escherichia coli. Its gene (GenBank GQ268963) was cloned into a pGEX-4T expression 
vector as a fusion protein with glutathione-S-transferase (GST).  BL21 cells transformed 
with the GST-Mus a 5 construct were employed for production of the protein. The 
conditions for protein expression were optimized by varying the temperature (25, 30 and 37 
°C) and duration of protein expression (3, 6 and 12 h). The level of protein production was 
analyzed by densitometry of the sodium dodecyl sulfate–polyacrylamide gel (SDS–PAG) 
after electrophoretic resolution of the respective cell lysates. The optimal protein expression 
for downstream processing was obtained after 12 h of cell growth at 25 °C upon addition of 
IPTG. In addition, since a large amount of rGST-Mus a 5 was detected in inclusion bodies 
we designed an enzyme assay for monitoring expression and solubility of GST fusion 
proteins targeted to inclusion bodies. The activity of rGST was assayed under denaturing 
conditions using a colorimetric assay and it was shown that rGST preserves 50% of activity 
in 4M urea. This assay was further successfully used to monitor rGST-Mus a 5 expression 
in inclusion bodies. 
Recombinant GST-Mus a 5 purified by glutathione affinity chromatography revealed a 
molecular mass of about 60 kDa. The IgE and IgG reactivity of the rGST-Mus a 5 was 
confirmed by dot blot and 2D blot analysis with sera of individual patients from subjects 
with banana allergy and polyclonal rabbit antibodies against banana extract, respectively. 
These results indicate that purified recombinant glucanase is a potential candidate for 
banana allergy diagnosis. 
 
Key words: Food allergy, recombinant allergens, banana, β-1, 3- glucanase, GST  
Scientific field: Life sciences 
Scientific discipline: Biochemistry 
UDK number: 577.112 
 
 
 
 
 
 
Naslov: Ispitivanje alergenih osobina rekombinantne glukanaze banane 
(Musa acuminata) 
Izvod 
Аlergije na hranu se definišu kao nepoželjne imunološke reakcije koje se javljaju svaki put 
prilikom konzumiranja odrеđene hranljive namirnice. Danas alergije na hranu predstavljaju 
značajan zdravstveni problem, i smatra se da oko 5% dece i 3-4% odraslih ljudi pati od 
ovog poremećaja, a uočena je i tendencija rasta broja alergičnih pacijenata. Istovremeno, 
čak i samo dijagnostifikovanje alergije na hranu predstavlja izazov, s obzirom da se u tu 
svrhu trenutno upotrebljavaju alergeni ekstrakti, koji su uzrok slabe specifičnosti i 
osetljivosti dijagnostičkih testova. Rekombinantna DNK tehnologija je razvijena tokom 80-
tih godina prošlog veka i pružila je mogućnost proizvodnje rekombinantnih proteina koji bi 
bili ekvivalentni prirodnim alergenima. Ovi proteini se proizvode kao biohemijski 
definisani molekuli sa ujednačenim strukturnim i imunološkim osobinama. Do danas je 
nekoliko stotina različitih alergena klonirano i eksprimirano u obliku rekombinantnih 
proteina. Ovi rekombinantni alergeni su omogućili znatno detaljniju dijagnostiku 
senzitizacionih profila alergičnih pacijenata. Iz ovog razloga je proizvodnja dobro 
okarakterisanih rekombinantnih proteina postala važno pitanje u farmaceutskoj industriji. 
Banana (Musa acuminata) je veoma popularno voće širom sveta i prisutno je tokom cele 
godine. Međutim, 1991. godine su prvi put opisani simptomi alergijske reakcije na ovo 
voće. Do danas je identifikovano 5 proteina koji čine molekulsku osnovu alergije na 
bananу. Ovi proteini su označeni kao Mus a 1 do 5. Alergen Mus a 5 predstavlja β-1, 3-
glukanazu iz PR-2 porodice proteina i učestvuje kako u odbrani biljke, tako i u mnogim 
drugim raznolikim fiziološkim i razvojnim procesima. 
Tokom izrade ove disertacije, β-1, 3-glukanaza je proizvedena kao heterologi protein u 
bakteriji Escherichia coli. Gen glukanaze iz banane (GenBank GQ268963) je ukloniran u 
ekspresioni vektor pGEX-4T sa glutation-S-transferazom (GST). BL21 ćelije 
transformisane sa GST-Mus a 5 konstruktom su korišćene za proizvodnju proteina. Uslovi 
za ekspresiju proteina su optimizovani variranjem temperature (25, 30 i 37°C) i dužine 
trajanja proteinske sinteze (3, 6 i 12 h). Nivo proizvodnje proteina je analiziran 
denzitometrijom SDS–PA gela nakon elektroforetskog razdvajanja ćelijskih lizata. 
Optimalna proizvodnja proteina za njegovo dalje procesovanje je dobijena gajenjem ćelija 
nakon dodatka IPTG na 25 °C tokom 12 h. S obzirom da je znatna količina rGST-Mus a 5 
detektovana u inkluzionim telima, tokom izrade ove disertacije osmišljen je enzimski esej 
za proveru ekspresije i solubilnosti GST fuzionih proteina u inkluzionim telima. Aktivnost 
rGST-a je merena pod denaturišućim uslovima i pokazano je da rGST zadržava 50% svoje 
aktivnosti u 4M urei. Ovaj esej je zatim uspešno korišćen i za detekciju ekspresije rGST-
Mus a 5 u obliku inkluzionih tela. 
 
GST-Mus a 5 prečišćen je afinitetnom hromatografijom sa glutationom i određena je 
molekulskа masа od 60 kDa. IgE i IgG reaktivnost izolovane glukanaze potvrđena je u “dot 
blot-u” i 2D imunoblotu sa pojedinačnim serumima osoba alergičnih na bananu, i sa 
poliklonskim zečijim antitelima na ekstrakt bananе. Dobijeni rezultati ukazuju da je 
prečišćena rekombinantna glukanaza dobar potencijalan kandidat za dijagnozu alergije na 
bananu. 
 
Ključne reči: Alergije na hranu, rekombinantni alergeni, banana, β-1, 3-glukanaza, GST 
Naučna oblast: Prirodno-matematičke nauke 
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 1. Introduction 
 
1.1. Immune system and allergy 
 
The immune system must distinguish between innocuous and pathological antigens to 
prevent unnecessary and self-destructive immune responses (Akdis, 2004). When the 
immune system exerts an inappropriate response that induces tissue damage, a condition is 
marked as hypersensitivity (Roith, 2006). Typically, hypersensitivities are classified into 
four different types (Marc, 2009). Nowadays, the most common form of hypersensitivity is 
allergic response, which is termed Type 1 or immediate hypersensitivity (Roith, 2006). 
 
Allergic reactions are symptomatic responses to a normally innocuous environmental 
antigen (Jacquet, 2009). The interaction of environmental and genetic factors can lead to 
the development of atopic disorders in some individuals, but not in others, following 
allergen exposure (Taylor, 2005). During the last 30 years, there has been a considerable 
increase in the incidence of atopic diseases in industrialized societies and it has been 
estimated that at least 20% of the population worldwide is susceptible to an atopic disease 
(Miescher, 2002). 
 
The generation of the allergen-specific CD4+ T helper (Th) cells provides the initial event 
responsible for the development of an allergic disease. The current view is that naïve T 
cells, under the influence of IL-4 differentiate into Th2 cells when they are activated by 
antigen-presenting cells (APCs) (Taylor, 2005). The secretion of IL-4, IL-5, IL-9 and IL-13 
and probably some other recently identified cytokines, such as IL-25, IL-31, and IL-33 by 
Th2 cells mediate the allergen-specific Th2 response characterized by the production of 
allergen-specific IgE antibodies (Jacquet, 2009). IL-4 and IL-13 induce immunoglobulin 
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(Ig) class switching in B cells, leading to excessive IgE production with subsequent mast 
cell activation and mediator release. IL-5 contributes to the development of eosinophilic 
inflammation and enhances mucus production of the airway epithelia (Gerhold, 2007). 
Diagnostic tests for food allergy frequently have poor specificity and sensitivity (Palacin et 
al., 2008). Therefore replacement of allergen extracts with a panel of IgE reactive 
molecules from particular allergen source is a promising strategy for the improvement of 
allergy diagnosis. 
 
The molecular basis of banana allergy has been related to five IUIS (International Union of 
Immunological Societies, www.allergen.org) nominated allergens: profilin (Mus a 1), class 
I chitinase (Mus a 2), non-specific lipid transfer protein (Mus a 3), thaumatin-like protein 
(Mus a 4) and beta-1,3-glucanase (Mus a 5). Beta-1,3-glucanase belongs to the PR-2 family 
of proteins and is involved in various physiological and developmental processes (Peumans 
et al., 2000). 
 
Unlimited availability of recombinant proteins have advantage over natural molecules 
regarding their unique feature such as purity and homogeneity, providing batch-to-batch 
consistency not achievable with natural molecule. The aim of this work was molecular 
characterization of recombinantly produced Mus a 5, in terms of primary structure, IgG and 
IgE reactivitivity for employment in component-resolved allergy diagnosis. 
1.1.1. Mechanisms of immune tolerance to allergens 
 
There has been a long-term belief, as well as experimental evidence, that the immune 
system has inducible peripheral mechanisms of immune tolerance to allergens (Akdis, 
2004). Dendritic cells (DCs) are cornerstones in the activation of the innate and adaptive 
immune system, as well as in the maintenance of peripheral tolerance (Soyer, 2013). 
 
Many studies report that dendritic cells, the most powerful antigen presenting cells (APCs), 
orchestrate the induction of Th1, Th2, Th9, Th17, Th22 or Treg responses (Jacquet, 2009; 
Soyer, 2013). Many factors are decisive in the process of Th polarization including the type 
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of antigen, the presence of microbial compounds, the route of exposure and the genetic 
background of the host. All these factors will act at the level of DC to induce signals 
triggering Th subset cell differentiation (Jacquet, 2009). During a healthy immune 
response, monocytes differentiate into tolerogenic DCs in the presence of granulocyte-
macrophage colony-stimulating factor (GM-CSF), CCL18, and prime T regulatory cells 
(Treg) to induce tolerance (Soyer, 2013).  
 
Indeed, Treg cells have been clearly implicated as potent inducers of a non-responsive state 
in several immune-mediated pathologies like autoimmunity and allergy. It has been shown, 
in allergy, that Treg cells can be transferred conferring specific tolerance to subsequent 
challenges with an allergen. In addition, depletion of the regulatory T cells can have a 
detrimental effect in allergic airway hyperreactivity (Agua-Doce, 2012).The differentiation 
of T-cell clones to Th1, Th2, Th9, Th17, Th22 and Treg cells is a complex event (Figure 1). 
 
Differentiation to the Th1 phenotype is induced by IL-12 and IFN-γ, which are secreted by 
DCs, and lead to the activation of signal transducers and activators of transcription (STAT) 
1 and STAT4. STAT1 stimulates expression of T-box transcription factor (T-bet), the main 
transcriptional factor of Th1 differentiation. Th2 cell development is promoted by IL-4, 
which signals through activation of STAT6 after engagement of IL-4R with GATA-3. 
GATA-3 is the main transcriptional factor of Th2 cells, and is important for Th2 cytokine 
production (Soyer, 2013). 
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Figure 1. Differentiation of T cells into effector CD4+ T cell lineages, Th1, Th2, Th17, and Treg 
cells is stimulated by the presentation of antigen by dendritic cells (DCs) to naïve T cells. Certain 
cytokines and other cofactors released from DCs and other cells induce the differentiation of naïve 
T cells, which involves the activation of distinct signaling cascades and transcription factors. Each 
effectors T-cell subset has unique functions in immune regulation (Soyer, 2013). 
 
Transcription factors are key molecules involved in the determination of Th1/Th2 balance. 
The shift toward Th2 determines allergic response, while Th1 cytokines are supposed to 
suppress these reactions. STAT6 plays an important role in signal transduction pathway 
used by IL-4 and IL-13, as well as in class switching to IgE and Th2 cytokine production 
(Kumar, 2012). 
 
T regulatory cells are thought to mediate the phenomenon of antigen-specific tolerance 
(Gerhold, 2007). Treg cells can be divided into three major subsets (Kumar, 2012). Natural 
Tregs (nTregs) develop in the thymus, express constitutively CD25 (IL-2Rα) and the 
transcription factor fork head box protein 3 (Foxp3), and act in an antigen-independent 
manner immunosuppresively (Gerhold, 2007; Chinen, 2004). In the periphery, a group of 
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adaptive antigen-specific Tregs (aTregs) develop from still unknown (CD25-) precursor 
cells in response to foreign antigens. Tregs of this type become CD25+ during their 
development; but only some of them express Foxp3 (Gerhold, 2007). 
 
Type 1 of regulatory cells (Tr1), also known as inducible Treg cells, are defined by their 
ability to produce high levels of IL-10 and transforming growth factor-β (TGF-β)(Agua-
Doce, 2012). Tr1 cells are induced by high and increasing doses of allergens. Allergen-
specific Th1 and Th2 responses are down-regulated by these Tr1 cells. Th3 cells, similar to 
Tr1 cells, are inducible upon activation with an appropriate antigen or anti-CD3 antibody 
and produce high levels of TGF-β, with variable amounts of IL-4 and IL-10 (Taylor, 2005; 
Braga, 2012). 
 
In healthy individuals, the immune response to allergens can be regarded as specific 
unresponsiveness of T cells or active peripheral tolerance induction by subsets of Treg cells 
(Soyer, 2013). There are several major mechanisms, by which Treg cells contribute to the 
control of allergen-specific immune responses (Figure 2) (Braga, 2012). IL-10 down-
regulates the expression of MHCII and other co-stimulatory molecules on 
monocytes/macrophages and dendritic cells. That way, Treg cells suppress antigen-
presenting cells that support the generation of effectors Th2 and Th1 cells (Braga, 2012). 
IL-10 is also a suppressor cytokine of allergen-induced proliferation of Th1 and Th2 cells 
(Taylor, 2005).  
 
Some studies showed that TGF-β, produced by Treg cells, can directly inhibit GATA3 
expression, thus impairing Th2 differentiation. Since the Th2 response is impaired, the 
production of IL-4 is diminished, and this has a direct impact on B-cell class switch, 
preventing IgE and favoring IgA production (Agua-Doce, 2012). Treg cells also have 
regulatory function on B cells by suppression of allergen-specific IgE and induction of 
IgG4, IgA or both. IL-10 has two major effects on B cells: it decreases ε-transcript 
expression and therefore IgE production, and enhances g4 transcript expression and IL-4-
induced IgG4 production (Braga, 2012). Furthermore, Treg cells also prevent allergic 
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inflammation through action on mast cells, basophiles and eosinophiles. Treg cells suppress 
FcεRI-dependent mast cell degranulation through cell-cell contact (Soyer, 2013). 
 
 
 
Figure 2. Suppression of Th2 cell-mediated features of allergic inflammation by Treg cells. Treg 
cells utilize multiple suppressor factors to regulate undesired activity of effector Th2 cells. IL-10 
and TGF-β suppress IgE production and induce the non-inflammatory immunoglobulin isotypes 
IgG4 and IgA, respectively. Furthermore, these two cytokines directly suppress allergic 
inflammation induced by effector cells such as mast cells, basophils and eosinophils. In addition, 
Th2 cells are suppressed by Treg cells and can therefore no longer provide cytokines such as IL-3, 
IL-4, IL-5, IL-9 and IL-13. These cytokines are required for the differentiation, survival and activity 
of mast cells, basophils, eosinophils and mucus-producing cells, as well as for the tissue homing of 
Th2 cells (red line indicates suppression, black line indicates stimulation) (Taylor, 2005). 
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1.1.2. Pathogenesis and mechanisms underlying the allergic responses 
 
The defining hallmark of an atopic disease is the production of specific IgE antibodies 
against allergens (Miescher, 2002). Allergen sensitization and the production of IgE is the 
first step in the development of an allergic disease (Bochner, 2004). Cytokines produced by 
allergen-specific Th2 play a central role in the regulation of the IgE response. IL-4 and IL-
13 are essential for the production of IgE antibodies (Miescher, 2002). 
 
Upon primary exposure, food allergens are captured by antigen presenting cells, especially 
dendritic cells (DCs). The allergens are internalized by DCs due to receptor-mediated 
endocytosis process, macropinocytosis, or phagocytosis. The allergens are detected by 
ubiquitin, and these ubiquitinized allergens move to the proteosomal complex and 
ultimately get degraded to peptide fragments. The degraded peptide fragments are 
presented by major histocompatibility complex class II (MHC II) and recognized by naïve 
CD4+ T cells. These CD4+ T cells differentiate into Th2 cells, especially in the presence of 
adequate amount of IL-4 (Kumar, 2012; Mills, 2003). 
 
Activation of the allergen-specific Th2 cells leads to expression of IL-4 and IL-13, which 
induce class switching to IgE (Stone, 2010). Isotype switching to IgE requires 2 signals. 
The first signal is provided by IL-4 and IL-13 and their receptors on B cells. Binding of IL-
4 and IL-13 to their receptors initiates a signaling cascade that results in the translocation to 
the nucleus of signal transducer and activator of transcription 6 molecules (STAT6) which 
becomes an active dimer after phosphorylation (Miescher,2002). STAT6 activates 
transcription at the IgE isotype-specific, Sε switch region (Stone, 2010). 
 
In addition to the switch signal provided by IL-4 and IL-13 a second signal for efficient 
activation of B cell is required.  The second signal is an interaction of CD40 on B cells and 
CD40-ligand on Th2 cells (Miescher, 2002). After activation by allergens, the subset of 
CD4+ T lymphocytes produces a spectrum of cytokines like IL-4, IL-5, IL-6, IL-9, Il-10 
and IL-13 that cause the increase of serum IgE levels and induction of eosinophiles, which, 
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in turn, mediate the clinical symptoms. The IgE immunoglobulin attaches to the FcεRI of 
mast cells or basophils (Kumar, 2012).  The FcεRI is a multimeric cell surface receptor 
composed of α-, β- and two γ-chains and exists in two isoforms. The α- and β- subunits are 
found to be involved in attachment of IgE, while γ- subunits are involved in 
phosphorylation process (Miescher, 2002). 
 
Upon secondary exposure to the allergen, IgE activates the allergic cascade effectively via 
the high-affinity receptor, FcεRI, on blood- and tissue cells (Kumar, 2012). The cross-
linking of FcεRI molecules initiates the association of the receptor with lipid rafts 
containing Lyn, a membrane anchored member of the Src family of protein tyrosine 
kinases. Lyn kinase trans-phosphorylates tyrosine residues in the immunoreceptor tyrosine-
based activation motif (ITAM) of FcεRI through the Src homology 2 (SH2) domain. This 
ITAM phosphorylation induces fully activation of Syk, which initiates a series of events 
such as generation of inositol triphosphate (IP3) (Saito, 2013). IP3 causes Ca2+ release from 
intracellular repository, including endoplasmic reticulum, which ultimately leads to mast 
cell degranulation (Kumar, 2012). 
 
Cross-linking of IgE-FcεRI complexes on the mast-cell surface by allergens leads, within 
minutes, to the so-called ``early phase`` of the allergic reaction, which involves mast-cell 
degranulation and the synthesis of lipid mediators (Gould, 2008). Prostaglandins, 
cytokines, leukotrienes, histamine, heparin, platelet-activation factor (PAF), eosinophil 
chemotactic factor of anaphylaxis, proteolytic enzymes and other mediators are secreted by 
degranulated mast cells or basophils. These mediators may cause smooth muscle dilatation, 
capillary disruption, local swelling and other symptoms. In some individuals, those 
reactions may occur very vigorously leading to anaphylaxis or sometimes even death 
(Kumar, 2012). A brief mechanistic pathway of allergies is given in Figure 3. 
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Figure 3. A brief outline of mechanistic pathway that occurs during allergen induced mast cell 
degranulation (Kumar, 2012). 
 
1.1.3. Molecular genetics of allergies 
 
It has been widely accepted that allergic diseases develop in atopic individuals and that they 
have a genetic basis. More than one gene is likely involved in the expression of atopy 
(Miescher, 2002). Atopy manifests itself as an IgE response to allergens. Traditionally, 
finding the gene responsible for the susceptibility to certain disease required the discovery 
of a biochemical or physiological abnormality leading to the isolation of an aberrant protein 
that was partially sequenced. This amino acid sequence was then used to produce an 
oligonucleotide to screen for the expressed gene, which could then be fully sequenced. 
However, in many diseases there is no known abnormal protein (Anderson, 1998). 
 
In order to identify genes that are relevant to atopic diseases two approaches have been 
followed. Firstly, a positional cloning, which links the inheritance of specific chromosomal 
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regions with the inheritance of the disease (Miescher, 2002; Cookson, 2000). The second 
method, the study of candidate genes, is based on the identification of polymorphisms in a 
gene, which is plausible candidate for being responsible for the disease (Miescher, 2002; 
Anderson, 1998). 
 
Such studies have identified several genes or loci that may be involved in atopy. On 
chromosome 11q13, in the region of gene encoding the β-subunit of the high affinity IgE 
receptor (FcεRI), two polymorphisms (ile/leu181 and val/leu183) have been reported 
(Anderson, 1998; Cookson, 2000). Linkage for atopy was also found with polymorphisms 
in gene cluster region on chromosome 5. The 5q23-31 region contains genes coding for IL-
3, IL-4, IL-5, IL-9 and IL-13 (Anderson, 1998). 
 
The MHC region on chromosome 6 has shown consistent linkage to asthma-associated 
phenotypes in several studies and may be considered to be a major locus influencing 
allergic diseases (Cookson, 2000). The major control of the allergen-specific IgE response 
appears to be associated with particular HLA-D types. For example, more than 90% of the 
IgE responders to the ragweed Amb V (Ra5) are HLA-Dw2 (Anderson, 1998). 
 
Determining the inheritance of a set of polymorphisms in a subject may allow the 
prediction of those at risk of developing allergic diseases and may allow disease prevention 
strategies to be more accurately directed. Similarly, the inheritance of a set of 
polymorphisms may indicate the clinical course, its severity, and its response to treatment 
(Anderson, 1998). 
 
1.2. Allergens as allergy elicitors 
 
The inquiry into which features make a protein allergenic is of a high interest to 
allergologists worldwide. It has been argued by some that any immunogenic protein 
presented in the right context and in sufficient quantity to the immune system of an atopic 
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individual can become an allergen. Other authors attribute allergenicity to certain 
architectural and structural features of the proteins. For this discussion, the comparison of 
allergenic and non-allergenic members in various protein superfamilies could provide 
further insights (Breitender, 2008). Even though a definite answer to the question: ``what 
makes an antigen an allergen? `` cannot be fully answered yet, the term allergen is used to 
describe two distinct molecular properties: the property to sensitize (i.e. induce the immune 
system to produce high-affinity antibodies, particularly of the IgE class) and the property to 
elicit an allergic reaction (i.e. to trigger allergic symptoms in a sensitized subject). 
Complete allergens have all these properties (Aalberse, 2000). 
 
Aspects of protein structure likely to be relevant for allergenicity are solubility, stability, 
size, and the compactness of the overall fold. One of the structural features clearly related 
to stability is the presence of disulfide bonds. Both inter- and intrachain disulfide bridges 
constrain the three-dimensional folds such that perturbation of the structure by heat or 
chemicals is limited and frequently reversible (Breitender, 2005). These aspects reflect 
dependency of allergenicity on transport over mucosal barriers and susceptibility to 
proteases. Posttranslational modifications may affect allergenicity in different ways. It may 
induce new epitopes and it may affect solubility, stability, size and susceptibility toward 
proteases. However, it is likely that features other than structure are more relevant for 
allergenicity. It is not realistic to assume that the requirements for sensitization to food 
allergies in early childhood are very similar to those for late-onset sensitization to airborne 
occupational allergens (Aalberse, 2000). 
 
1.2.1. Nomenclature of allergens 
 
The biochemistry of allergens is underpinned by a Linnean system of nomenclature that is 
maintained by the World Health Organization (WHO) and International Union of 
Immunological Societies (IUIS) Allergen Nomenclature Sub-Committee. The systematic 
nomenclature was adopted by WHO/IUIS and published in the Bulletin of the WHO in 
1986 and in revised form in 1994. Allergens are named using the first 3 letters of the genus, 
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followed by a single letter for the species and a number indicating the chronologic order of 
allergen purification (Chapman, 2007). 
 
The massive accumulation of sequence data of, particularly, plant proteins in recent years 
has made the classification of allergens into protein families possible. By comparing 
sequences and structures, related proteins can be grouped together into families (if they 
have residue identities of 30% or greater, or if they have lower sequence identities, but their 
functions and structures are very similar), and related families can be grouped together into 
superfamilies (Radauer, 2007). 
 
1.3. Food Allergy 
 
1.3.1. Prevalence and risk factors 
 
Adverse reactions to food can be classified as either IgE-mediated or non-IgE mediated. 
Non allergic adverse reactions are commonly caused by host factors, such as enzyme 
deficiencies, or by inherent toxic properties of food, as is the case with food poisoning 
(Sicherer, 2006). Food allergy, on the other hand, is defined as an ‘adverse health effect 
arising from a specific immune response that occurs reproducibly on exposure to a given 
food’ (Boyce, 2010). Currently, food allergy is a major health problem, with an estimated 
prevalence of about 5% in young children and 3-4% in adults and the prevalence is 
increasing (Sicherer, 2010; Burks 2012). The major food allergens are milk, egg, peanuts, 
shellfish, fish, wheat, and soy (Sicherer, 2010). In most cases exposure to these food 
allergens causes only mild allergic reactions. However, in severe cases anaphylaxis can be 
induced, mainly in people allergic to peanut and other tree nuts (Koplin, 2011). 
Allergies are the result of a complex interplay between genetic predisposition and 
environmental factors. Specific genetic loci that may modulate individual risk of food 
allergy remain to be identified (Hong, 2009). Some environmental factors, such as delayed 
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introduction of solid foods in infants, effects of breastfeeding, and early colonization of the 
intestine by appropriate microbiotica have been shown to be important for the development 
of a healthy immune system. In addition, the acid content of the stomach also plays a role 
in allergic sensitization, since an increased pH is associated with increased allergic 
sensitization (Cochrane, 2009; Untersmayr, 2003). Nevertheless, it is not yet fully 
understood how all these factors play a role in the development of food allergy. 
 
1.3.2. Immune system of the gastrointestinal tract 
 
The gastrointestinal mucosa is an extensive structure responsible for digestion and 
absorption of nutrients as well as protection from pathogenic organisms (Sicherer, 2006). 
The highly elaborate architecture of the intestinal mucosa increases the total intestinal 
surface to about 300–400 m2, with a total length of the small and large intestine of 
approximately 8 m. The intestinal mucosa is colonized with numerous (up to 1014) luminal 
bacteria derived from more than 500 different species (Schenk, 2008). The intestinal 
barrier, formed by a monolayer of epithelial cells, displays a number of specialized 
protective adaptations: the cells form tight junctions that act as a physical barrier, goblet 
cells secrete thick mucus which forms a viscose layer, and paneth cells secrete microbicidal 
a-defensins, lysozyme and cathelicidins (Frey, 1996; Boman, 2000). Approximately 70% of 
all the lymphocytes of the human body are concentrated in the intestinal intraepithelial and 
subepithelial layers, and the largest pool of tissue macrophages is located in the intestinal 
wall (Macpherson, 2004). These features, coupled with the presence of proteolytic 
enzymes, bile salts, and extreme pH needed for digestive processes results in a highly 
functional defense system. In addition, components of the innate immune system (NK cells, 
polymorphonuclear leukocytes, macrophages) and adaptive immune system (intraepithelial 
lymphocytes, Peyer’s patches,  IgA, cytokines) form an active barrier towards foreign 
proteins (Chehade, 2005; Mowat, 2003). 
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 1.3.3. Oral tolerance 
 
Despite the complex interplay of the mucosal system, approximately 2% of intact food 
proteins are absorbed through the mature GI tract and reach the lymphatic and portal 
circulation. (Sicherer, 2006) After ingestion, most food proteins are digested by gastric 
acids and enzymes in the stomach and intestines.  
 
 
 
Figure 4. Antigen sampling in the gut. A) Dendritic cells extend processes through the epithelium 
and into the lumen. B) M cells overlying Peyer’s patches take up particulate antigens and deliver 
them to subepithelial dendritic cells. C) Soluble antigens possibly cross the epithelium through 
transcellular or paracellular routes to encounter T cells or macrophages in the lamina propria 
(Chehade, 2005). 
 
The remaining food proteins and peptides are subsequently transferred from the lumen to 
the mucosa via gut epithelial cells, either by specialized M cells present in Peyer’s patches, 
through epithelial cells, or by direct sampling of mucosal dendritic cells (Figure 4) (Mowat, 
2003; Burks, 2008). In the mucosa, dendritic cells process these proteins and peptides, 
move to T cell areas and present them on MHCII where they can interact with naïve T cells. 
The presence of costimulatory molecules is important in determining the subsequent 
immune response: interaction of CD28 present on T cells with CD80 and CD86 present on 
dendritic cells induces T cell activation, whereas interaction of CD80 and CD86 present on 
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dendritic cells with CTLA-4 present on T cells down-regulates T cell activation (Krummel, 
1995; Vandenborre, 1999). 
 
In normal individuals, presentation of processed proteins and peptides by dendritic cells to 
naïve T cells will lead to the induction of oral tolerance, a state of active inhibition of 
immune responses to antigens encountered in the intestine. Oral tolerance allows 
individuals to encounter immense quantities of dietary protein and commensal bacteria 
without inciting a dynamic immune response (Chehade, 2006).  However, in certain 
individuals, caused by factors mentioned before, presentation of the food protein on MHCII 
results in the induction and activation of Th2 cells which then stimulate B cells to produce 
allergen specific IgE leading to sensitization and a subsequent allergic reaction upon 
repeated exposure. Food hypersensitivity likely results from either a failure in establishing 
oral tolerance or a breakdown in existing tolerance. Several factors, including antigen 
properties, route of exposure, and genetics and age of the host, contribute to the failure of 
oral tolerance (Burks, 2008). 
 
1.3.4. Food allergens 
 
Aspects of protein structure that are likely relevant for allergenicity are solubility, stability, 
size, and compactness of the overall fold. In fact, most allergens are relatively small, 
hydrophilic, and stable proteins, apparently lacking bacterial homologues (Emanuelsson, 
2007). These aspects reflect the dependency of allergenicity on transport over mucosal 
barriers and susceptibility to proteases (Hauser, 2008). 
 
Despite the wide range of foods that humans consume, surprisingly few foods account for 
the vast majority of food allergies. Milk, egg, peanut, wheat, and soy are responsible for 
most food-induced reactions (Sampson, 2004). Two forms of IgE-mediated food allergy 
have been proposed. Class 1 food allergy results from sensitization through the GI tract. 
The class 1 food allergens are generally 10 to 70 kDa in size and highly stable when 
subjected to heat, acid, or proteases. Examples of class 1 food allergens include milk 
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(caseins), peanut (vicillins), egg (ovomucoid), and nonspecific lipid transfer proteins 
(Sicherer, 2006). On the other hand, sensitization can be facilitated if the gastrointestinal 
tract is surpassed and the antigen is presented via an alternative route. An example of this is 
the oral allergy syndrome (OAS), also known as the food-pollen syndrome. Oral tolerance 
is not induced since sensitization occurs through the respiratory tract. The patient is 
sensitized with pollen via the airways and exhibits an allergic reaction to a food antigen 
with a structural similarity to the pollen protein (Fernandez-Rivas, 2006; Bohle, 2007). 
Class 2 food allergy results from sensitization to inhalant allergens that are partially 
homologous to proteins in certain fruits and vegetables, and principally occurs in 
adolescents and adults. Class 2 allergens are heat labile and susceptible to digestive 
processes. Consequently, symptoms occur when the food is ingested in the raw form, but 
not when cooked. Pollen allergic individuals are at risk due to the homology between 
specific pollen proteins and proteins in certain foods (Sampson, 2006). Of patients with 
allergic rhinitis, it has been estimated that 23 to 76% of patients experience oral symptoms 
to at least one food (Sicherer, 2001). The cooked version of the foods is typically tolerated 
due to disruption of the protein conformation or tertiary structure (Sampson, 2006). 
 
1.3.5. Plant-derived food allergens 
 
So far the allergen list of the International Union of Immunological Societies (IUIS) 
allergen nomenclature subcommittee comprises 130 plant-derived food allergens. Based on 
sequence homology these allergens can be classified into only 27 out of 9,000 known 
protein families. These families comprise the prolamin and cupin superfamilies, 
pathogenesis related proteins, profilins, thaumatin-like proteins, oleosins, expansins, a 
number of enzymes and protease inhibitors among others (Hauser, 2008). Many of the 
known plant food allergens are homologous to pathogenesis-related proteins (PRs), proteins 
that are induced by pathogens, wounding, or certain environmental stresses. PRs have been 
classified into 14 families. Allergens other than PR homologs can be allotted to other well-
known protein families. In fruits and vegetables with high water content, such as cherries, 
papayas, bananas, or avocados, that are prone to fungal attack, the chitinases, proteases, and 
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antifungal proteins are the predominant allergens. The allergens in hard and dry seeds such 
as wheat berries, rice, mustard seeds, or soybeans fall into two classes: the seed storage 
proteins and the enzyme inhibitors. They prevent the endosperm from being digested by 
insects or fungi (Breiteneder, 2000).  
 
In general, any innocuous environmental antigen that is able to trigger a Th2 or an IgE 
response is defined as allergen. Depending on the percentage of allergic individuals 
reacting to a protein of a given allergenic source, major (> 50%) and minor (< 50%) 
allergens can be distinguished. Both major and minor allergens can be found in most plant 
food protein families. The seed storage proteins for example are considered as major 
allergens of the prolamin superfamily that are likely to act as potent class I food allergens. 
In contrast, profilins and PR-proteins are regarded as class II food allergens due to their 
instability to heat and gastric digestion. For instance, profilin has been identified as a major 
allergen in patients suffering from pollen-food syndrome caused by melon. Digestibility 
analysis of melon profilin revealed its stability in human saliva but not in simulated gastric 
fluid, which is typical for class II food allergens (Rodriguez-Perez, 2003). 
 
1.3.6. Diagnosis of food allergy 
 
The diagnostic approach to allergic food reactions includes assessing the patient’s medical 
history, a physical examination, and identification of the suspected food. Elimination diets 
are used both in diagnosis and in therapy of food allergies (Sampson, 2004) Identification 
of the suspected food also includes skin tests and in vitro assays, which can confirm a 
sensitization to the food. However, for the conclusive diagnosis of a food allergy it is 
necessary to demonstrate, by an oral challenge, that the food to which a sensitization has 
been found is responsible for the patient’s symptoms (Fernandez- Rivas, 2004). 
 
Lewis and Grant described skin prick testing (SPT) for the first time in 1924 and it was 
modified by Pepys in 1970. This is the easiest, fastest, and less expensive method to 
identify specifc IgE antibodies (Demoly, 2003). Drops of different glycerinated allergen 
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extracts, placed on the volar surface of the forearm are passed by hypodermic needle at a 
low angle with the bevel facing up into the epidermal surface. The needle tip is then gently 
lifted upward to elevate a small portion of the epidermis not inducing bleeding. The 
immediate reaction (wheal and erythema) is measured after 15 to 20 minutes. A positive 
test is considered when diameter wheal is greater than 3 mm (Hamilton, 2003). Several 
factors contribute to variability in the prick test results. Bleeding and dermographism can 
lead to a false-positive wheal and erythema. False-negative tests are consequences of 
antihistamine use, low potency of extracts and poor technique (Demoly, 2003). Nowadays, 
the skin prick test is usually done with fresh foods. In this test the lancet is plunged several 
times into the food immediately before pricking the patient’s skin with it. The 
inconveniences of the prick–prick test are the impossibility of standardization and the 
dependence on the availability of the fresh food (Ortolani, 1989; Fernandez- Rivas, 2004). 
 
Allergen-specific IgE antibody (sIgE) in vitro assays have developed significantly over the 
past 40 years and continue to evolve in the areas of allergen characterization, antibody 
detection, and instrumentation. Originally described in the late 1960s, the 
radioallergosorbent test (RAST) was the first routine technique used for determining sIgE 
in serum (Hamilton, 2003). This ‘first generation’ assay employed cyanogen bromide-
activated paper discs as the solid phase (allegrosorbent) and used a birch pollen specific IgE 
calibration curve from which the levels of sIgE could be interpolated. Results were semi-
quantitative and organized into classes of reactivity related to skin prick test positivity. 
Second generation methods, introduced in the early 1990s, offered marked improvements 
in assay convenience and performance. These included: developments in solid phase 
allergosorbent materials or use of a liquid-allergen matrix resulting in enhanced antigen–
antibody kinetics and assay sensitivity, the use of nonisotopic detection methods 
(spectrophotometry, fluorimetry, enzyme enhanced chemiluminescence), reporting of 
quantitative sIgE results (kU/L) standardized to a WHO International Reference preparation 
for IgE. In addition, systems became semiautomated, resulting in faster turn-around times 
for results. Further refinements have been introduced with ‘third generation’ assays, most 
notably in the extension of the lower limit of detection to 0.1 kU/L, and in the availability 
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of random access automated analytical platforms (Crameri, 2006; Hamilton, 2004; 
Ahlstedt, 2006; Ebo, 2006). 
 
Skin prick tests and in vitro IgE assays are useful methods to demonstrate the presence of 
food specific IgE antibodies, but they do not establish the diagnosis of clinical food allergy. 
The oral challenge is the diagnostic test which provides conclusive evidence of a food 
allergy (Fernandez-Rivas, 2004; Bock, 1988) Oral food challenges may be performed 
openly (patient and physician are aware of the food ingested), single-blind (only the 
physician knows the content of the challenge) or double-blind (neither the patient nor the 
physician is aware of the content of the challenge). The blind challenges may be placebo-
controlled. The double-blind placebo controlled food challenge (DBPCFC) is considered 
the gold standard for the diagnosis of food allergy (Sampson, 1999). Food challenges are 
performed in the hospital where emergency care is immediately available. The food is 
administered to the patient in fasting conditions, starting with a dose unlikely to provoke 
symptoms, according to the eliciting dose reported in the medical history or in the last 
positive provocation test. Incremental amounts of food are given at time intervals slightly 
longer than expected to produce symptoms, until a positive reaction appears or the patient 
eats a normal amount of the food (Fernandez- Rivas, 2004). 
 
 
1.3.7. Therapy of food allergies 
 
Currently, the primary recommendation for food allergy patients is strict avoidance of the 
allergenic substance. Antihistamines and corticosteroids are used to treat acute allergic 
symptoms and in anaphylaxis epinephrine is used as the first line of treatment. However, 
these drugs only ameliorate symptoms and do not stop or cure progression of the disease 
(Sicherer, 2006; Burks, 2012). In addition strict avoidance of the allergenic food is also 
difficult to achieve. Patients have inadvertent cross contact with allergens or foods that 
have hidden allergens (Sicherer, 2006). One study illustrated that for 156 reactions to 
peanut and tree nuts, 50% of accidental ingestions in food establishments were due to 
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“hidden ingredients. This illustrates the difficulties that food-allergic patients face with 
daily experiences, such as purchasing prepared foods or eating in restaurants (Furlong, 
2001). 
 
A potentially curative treatment for (food) allergy is allergen-specific immunotherapy 
(SIT). SIT is already used for more than a hundred years as a desensitizing therapy and is 
presently successfully used to treat allergic rhinitis, asthma and wasp and bee venom 
hypersensitivity (Fitzhugh, 2011). The aim of SIT is to induce peripheral T cell tolerance 
and to increase the thresholds for IgE mediated mast cell and basophile activation. The high 
success rate of SIT (varying from 80-90 %, depending on the antigen used) is promising. 
However, disadvantages include the long duration of the treatment (3-5 years), the amount 
of allergen injections needed (about 80) and allergic side effects. Key mechanisms of 
successful SIT are the induction of regulatory T cells and an increase of IgG4 that may 
capture the allergen before reaching effector cell-bound IgE (Kunding, 2010). 
Unfortunately conventional immunotherapy is nоt as effective in treating food allergies. 
Recently, both sublingual immunotherapy (SLIT), where the allergen is held under the 
tongue, and oral immunotherapy (OIT), where the allergen is simply swallowed, have 
shown promise as potential treatments (Burks, 2008). The implementation of recombinant 
proteins with an altered IgE-binding epitope may be a form of immunotherapy that holds 
future promise. The altered IgE-binding epitopes could prevent binding of the patient’s IgE 
to the engineered protein within the vaccine (Sampson, 2004). 
 
1.4. Recombinant DNA technology 
 
Technology of recombinant DNA or genetic engineering is a new field of biotechnology 
that developed in the last three decades. Techniques of genetic engineering allow the 
possibility of introduction and understanding of complex biological processes such as 
mechanism of eukaryotic gene expression during development, immunological response, 
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cell division etc. These techniques have found a broad application not only in scientific 
research but also in many other fields of life (Allison 2007). 
Employement of recombinant DNA technology allows production of any protein-encoding gene . 
The target gene is derived from the original chromosome using an endonuclease enzyme and then 
integrated in a vector as a plasmid or phage. After that, the vector is transformed into a prokaryotic 
or eukaryotic expression system. The target protein is produced in desired amounts by culturing 
these microorganisms. Cloning of DNA from any organism entails five general procedures:  
 
1. Cutting the DNA of interest at precise locations by sequence-specific endonucleases 
(restriction endonucleases)  
2. Selection of cloning vector (a delivery agent), typically plasmids or viral DNAs 
3. Joining two DNA fragments covalently by using DNA ligase  
4. Moving recombinant DNA from the test tube to a host cell that provides the 
machinery needed for DNA replication 
5. Selection and identification of host cells that contain recombinant DNA (Allison, 
2007). 
 
The bacterium Escherichia coli (E. coli) is the first organism used for recombinant DNA 
work and still the most common host cell. E. coli has many advantages: its DNA 
metabolism (like many other of its biochemical processes) is well understood, many 
naturally occurring cloning vectors associated with E. coli, such as plasmids and 
bacteriophages, are well characterized; and techniques are available for moving DNA from 
one bacterial cell to another. E. coli can also be used for amplification of DNA in large 
quantities so that it can be introduced into the desired host cells, such as mammalian, yeast 
or special bacterial cells. The host cells will then synthesize the foreign protein from the 
recombinant DNA. After the cells are grown in vast quantities the foreign recombinant 
protein can be isolated and purified in large amounts. Recombinant DNA technology is not 
only an important tool in scientific research, but it has also affected the diagnosis and 
treatment of diseases and genetic disorders in many areas of medicine (Davies 1981). 
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However, high levels of recombinant protein expression in E. coli can lead to the formation 
of insoluble inclusion bodies, which represent a set of structurally complex aggregates 
often perceived to occur as a stress response when the recombinant protein is expressed at 
high rates (Sorensen and Mortensen, 2005).  
 
1.4.1. Recombinant fusion proteins  
 
The purification of recombinant proteins can be simplified by incorporating a tag of known 
sequence into the protein. It is also a marker for expression and facilitates detection of the 
recombinant protein, which may simplify downstream purification protocol. The two most 
commonly used tags are glutathione-S-transferase (GST) and 6 × histidine residues (His)6.  
 
1.4.2. GST fusion proteins 
 
Yields of active, correctly folded recombinant proteins can be improved by using a cloning 
strategy in which the target protein is linked to a fusion partner, leading to high yield 
expression of the protein in soluble form (Hannig and Makrides, 1998). Glutathione S-
transferase (GST) is among the most frequently used fusion partners. The crystal structure 
of recombinant Schistosoma japonicum GST has been determined and matches that of the 
native protein. Recombinant fusion proteins containing the complete amino acid sequence 
of GST exhibit a functional GST enzymatic activity.  In addition to improving solubility, 
GST allows detection of the expressed recombinant protein using enzyme assays and GST-
specific antibodies, and also facilitates recombinant protein purification (McTigue et al., 
1995). Although most GST fusion proteins are expected to be soluble, many of them, even 
relatively small ones (40-50 kDa), are partially or completely insoluble following lysis of 
prokaryotic cells (Frangioni and Neel, 1993; Hansen and Eriksen, 2007). Therefore GST 
fusion proteins accumulated in inclusion bodies are considered to be undetectable by GST-
tag assays, designed for quantitative measurement of GST activity under native conditions. 
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1.4.3. Production of reagents for allergy diagnosis by recombinant DNA 
technology 
 
When the allergen nomenclature system was adopted in 1986, allergens were mainly 
identified based on their electrophoretic and chromatographic behavior and by reactivity to 
antisera. This was not only unsatisfactory as far as standardization is concerned, but the 
processes of allergic sensitization and immunotherapy could not be studied in the 
framework of antigen processing and B- and T-cell epitopes. Recombinant technologies 
developed in the 1980s permitted the cloning of allergens, beginning with the major house 
dust mite allergen Der p 1 and hornet allergen Dol m 5 (Fang et al., 1988; Thomas et al., 
1988). After this, a wave of cloning with IgE immune screening resulted in the cloning of 
Der p 2, Der p 5, Bet v 1, Bet v 2, and Dac g 2 along with Fel d 1 cloned (Fritsch et al., 
1998; Lynch et al., 1997; Seppälä et al., 2005). Recombinant allergens have been used to 
define the important allergens for a wide range of allergies and to develop new types of 
immunotherapy, some of which have shown efficacy in human trials. The pure recombinant 
allergens have been used to solve the tertiary structures of these proteins. Proprietary 
recombinant allergens are now being used in improved diagnostic tests (Asturias et al., 
1997; Gessler and Patocchi, 2007; Niederberger et al., 2001). 
Recombinant DNA technology provides the means for producing allergens that are 
equivalent to their natural counterparts and also genetically engineered variants with 
reduced IgE-binding activity. The proteins are produced as biochemically defined 
molecules with consistent structural and immunologic properties. Several hundred allergens 
have been cloned and expressed as recombinant proteins, and they can provide the means 
for making a very detailed diagnosis of a patient's sensitization profile. Clinical 
development programs are now in progress to assess the suitability of recombinant 
allergens for both subcutaneous and sublingual immunotherapy. Recombinant 
hypoallergenic variants, which are developed with the aim of increasing the doses that can 
be administered while at the same time reducing the risks for therapy-associated side 
effects, are also in clinical trials for subcutaneous immunotherapy. Grass and birch pollen 
preparations have been shown to be clinically effective, and studies with various other 
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allergens are in progress. Personalized or patient-tailored immunotherapy is still a very 
distant prospect, but the first recombinant products based on single allergens or defined 
mixtures could reach the market within the next couple of years (Barber et al., 2009; Heiss 
et al., 1999). 
A great variety of recombinant plant, mite, mold, mammal, and insect allergens have been 
expressed in heterologous hosts (e.g., Escherichia coli). The number of biologically active 
recombinant allergens available for experimental, diagnostic, and therapeutic purposes is 
increasing tremendously. Recombinant allergens have proven to be valuable tools to 
investigate T-cell and B-cell recognition of allergens as well as to study mechanisms of 
specific IgE regulation. The immunologic equivalence of many relevant recombinant 
allergens with their natural counterparts has been demonstrated, and the three-dimensional 
structures of several recombinant allergens have been described recently (Kaiser et al., 
2003; Markovic-Housley et al., 2003). Recombinant allergens have been used for 
successful in vitro, as well as in vivo, allergy diagnosis, and work is in progress to produce 
recombinant allergen derivatives with reduced anaphylactic potential to improve current 
forms of immunotherapy (Asturias, 2009; Gafvelin et al., 2007; Holm et al., 2004; Li et al., 
2003; Sampson et al., 2003). 
By using recombinant DNA technology, defined and safe allergy vaccines can be produced 
that allow us to overcome many, if not all, of the problems associated with the use of 
natural allergen extracts, such as insufficient quality, allergenic activity, and poor 
immunogenicity. Some of these vaccines have undergone successful clinical evaluation up 
to phase III studies. Furthermore, they introduce a strategy for allergen-specific 
immunotherapy based on recombinant fusion proteins consisting of viral carrier proteins 
and allergen-derived peptides without allergenic activity, which holds the promise of being 
free of side effects and eventually being useful for prophylactic vaccination (Bousquet et 
al., 1998). 
A large percentage of allergenic proteins are of plant origin. Hence, plant-based expression 
systems are considered ideal for the recombinant production of certain allergens. First 
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attempts to establish production of plant-derived allergens in plants focused on transient 
expression in Nicotiana benthamiana infected with recombinant viral vectors (Schmidt et 
al., 2008). Accordingly, allergens from birch and mugwort pollen, as well as from apple 
have been expressed in plants. Production of house dust mite allergens has been achieved 
by Agrobacterium-mediated transformation of tobacco plants. Beside the use of plants as 
production systems, other approaches have focused on the development of edible vaccines 
expressing allergens or epitopes thereof, which bypasses the need of allergen purification. 
The potential of this approach has been convincingly demonstrated for transgenic rice seeds 
expressing seven dominant human T cell epitopes derived from Japanese cedar pollen 
allergens. Parallel to efforts in developing recombinant-based diagnostic and therapeutic 
reagents, different gene-silencing approaches have been used to decrease the expression of 
allergenic proteins in allergen sources. In this way hypoallergenic ryegrass, soybean, rice, 
apple, and tomato were developed (Holm et al., 2004).    
 
1.5. Component resolved allergy diagnosis 
 
Employing allergen extracts for diagnosis and treatment is widespread and supported by a 
long and successful clinical tradition. However, based on the knowledge that has been 
gathered during the last 20 years of in vitro allergy diagnostics, extract-based approaches 
for diagnosis and treatment are controversially disputed. Above all, biological extracts are 
heterogeneous mixtures of allergenic and non-allergenic components. The actual allergenic 
molecules may only account for a minor fraction of the total content of the extract. Most 
allergen sources (e.g., birch pollen, animal dander, storage mites, etc.) have at least several 
major and minor allergen molecules. Standardized mixtures containing all the relevant 
allergens in the appropriate (biologically and diagnostically relevant) concentrations are 
difficult or even impossible to produce and the performance of commercially available 
allergen extracts from different manufacturers can therefore vary significantly. This is due 
to several reasons. Firstly, some allergens might resist even sophisticated extraction 
procedures and may therefore be absent or under-represented in the resulting extract. The 
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extractability of an individual allergen is a major prerequisite for test quality as it directly 
affects the assay sensitivity. Secondly, variable allergen stability leading to the partial or 
complete degradation of allergens during the extraction procedure could potentially 
interfere with the production of high quality extracts. Thirdly, biological materials are 
intrinsically heterogeneous regarding their allergen content. For example, when collecting 
tree pollen or fruit, the expression of certain allergens is affected by environmental factors, 
such macro- or micro-climate, pollution, or the developmental stage of the collected pollen. 
When considering food allergens, many different breeds exist for the common species and 
their allergen content is known to be different. Also protein content varies greatly with the 
ripening state so extracts can show a significant difference in composition and/or 
allergenicity (Gavrovic-Jankulovic et al. 2005). In addition, biological raw materials may 
be contaminated by compounds of extrinsic origin. For example, animal hair and dander 
can contain mites and even a fraction of these alien allergens may eventually lead to false-
positive results when the corresponding extracts are used for testing in certain allergic 
patients (van der Veen et al. 1996). Preparations of fruit or vegetable extracts can be 
contaminated with moulds or herbicides which can also induce false-positive results. 
Finally, many biological sources contain allergens with a strong potential for cross-
reactivity. Cross-reactivity originates from IgE antibodies binding to structurally similar 
epitopes from homologous proteins contained in different species. The use of 
heterogeneous extracts containing such structures bears the risk of producing false-positive 
or clinically irrelevant results. 
During the previous decade, a greater understanding of the problems mentioned above has 
led to numerous research activities focused on improving the standardization of the 
allergens being used for testing as well as for treatments (van Ree et al., 2004). 
Panels of recombinant allergens are available for many of the most important allergen 
sources (Barber et al., 2009; Bublin et al., 2010; Heiss et al., 1999; Pittner et al., 2004). 
These panels are designed to assemble the epitope complexity of their biological 
counterparts. Testing with these purified recombinant (or natural) allergenic components 
allows the majority of allergic patients to be diagnosed correctly and has several other 
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benefits. First and most importantly, assay standardization using well-characterized single 
molecules is superior to testing even with well standardized extracts and it also has positive 
effects on assay sensitivity and specificity. Moreover, the IgE-reactivities of an individual 
patient can be resolved at the level of individual disease-eliciting components. Hence, the 
term Component-Resolved Diagnosis (CRD) was introduced for this particular diagnostic 
approach. In certain cases the resulting reactivity pattern of serum IgEs can be used to 
improve the treatment for an individual patient significantly. For example, in the house dust 
mite (HDM), Dermatophagoides pteronyssinus, more than 20 allergens have been 
identified so far (Pittner et al., 2004). Patients who are sensitized against HDM could be 
tested at least for the major allergens Der p 1 and Der p 2 as well as for Der p 10, a minor 
allergen with a high potential for cross-reactivity. Since HDM extracts are generally 
standardized only for their content of Der p 1 and Der p 2, a patient who does not have 
specific IgE against either of the two proteins will probably not benefit from specific 
immunotherapy with HDM extracts. On the other hand, if the patient sample reacts with 
Der p 10 they are most probably sensitized against other mite species as well (e.g. D. 
farinae), and should not be treated with HDM extracts (Pittner et al., 2004). A similar 
constellation can be found in the European White Birch, Betula verrucosa. Extracts of this 
species produced for specific immunotherapy (SIT) are usually standardized against the 
major allergen Bet v 1 to which more than 90% of all patients have specific IgE. Patients 
who are mono-sensitized against this particular allergen can therefore be considered highly 
suitable for receiving SIT. On the contrary, an exclusive sensitization towards the minor 
birch allergen Bet v 2 makes SIT not recommendable for two reasons. Firstly, the allergen 
might not be present to a sufficient extent in the extract used for therapy and secondly, Bet 
v 2 belongs to the protein family of highly cross-reactive profilins that can be found in a 
wide range of biological sources (http://www.allergen.org/viewallergen.php?aid=130). 
Therefore, cross-reactivity towards an allergen of a different biological source has to be 
considered as the primary cause of the reactivity against birch pollen extract (Mobs et al., 
2010). 
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In other cases, CRD may help to reveal the route of sensitization of a particular allergen 
and this information can be used to prevent further allergen exposure more effectively. For 
example, in natural rubber latex (Hevea brasiliensis) reactivity against the major allergens 
Hev b 1 and Hev b 3 correlates with subcutaneous sensitization that has been acquired via 
previous surgery. Patients with Spina bifida (SB) who typically have several surgical 
treatments in the first few years of life often react with these two allergens. On the other 
hand, the allergens Hev b 2, Hev b 4 and Hev b 6 are more frequently the cause of 
occupational allergy (e.g. in health care workers) who come into contact with latex 
products via skin exposure (Levy and Leynadier, 2001). Moreover, a significant percentage 
of latex-extract positive patients may have been sensitized against a cross-reactive allergen, 
such as a profilin (e.g. Bet v 2). Clinically non-relevant cross-reactions against so-called 
cross-reactive carbohydrate determinants (CCD) have been described as the cause of false-
positive in vitro results when testing for latex (Coutinho et al., 2008).  
Determination of the precise allergy-eliciting molecule may help patients to take preventive 
life-saving measures which are particularly important in patients who are prone to systemic 
reactions when they come into contact with a particular allergen. For example, allergens of 
the lipid transfer protein (LTP) family are frequently found in tree nuts (e.g. peanut and 
hazelnut) and fruits (e.g. peach and cherry) and these allergens are strong elicitors of life-
threatening systemic reactions (Schocker et al., 2004). Other allergens of the same 
biological sources (e.g. Cor a 1, Ara h 1) have not been found to induce severe reactions in 
the affected patients. Therefore, using CRD with the corresponding allergenic molecules 
can be used to provide identification of patients who are prone to systemic reactions and 
equip them with an appropriate emergency set. 
Despite these promising results, CRD procedures are not yet established in routine 
diagnostic settings. Basically, there are two reasons for this: firstly, even if a 
comprehensive IgE reactivity profile could be obtained with a panel of recombinant 
allergens therapies based on the same molecules are still in a proof-of-concept stage of 
development. Secondly, only very few tests based on recombinant allergen panels are 
commercially available and these panels still lack important allergens. Allergy diagnosis on 
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the basis of single molecules would require a large number of individual allergens 
contained in the test format. For example, a comprehensive CRD-based test for allergy 
against grass pollen (e.g., timothy grass), mites (e.g., Dermatophagoides pteronyssinus) and 
latex (Hevea brasiliensis) would have to employ at least 30 individual protein components. 
Still this test could lack components of some other important species (e.g. other grass 
pollen and mites) that might be of relevance. Also, some naturally occurring allergen 
sources might contain allergens that have not been identified yet. As a consequence, a small 
percentage of patients would go undiagnosed if not all the available allergens are employed 
in the assay. Moreover, for many natural allergens a large number of isoforms has been 
identified and each of these isoforms might exhibit a (slightly) different IgE binding 
capacity in vitro (Corti et al., 2005; Sowka et al., 1999). It has also been shown that some 
recombinant allergens bind IgE with high affinity and resemble their natural counterpart 
quite well, whereas other artificial molecules only bind a minor fraction of IgE in contrast 
to the purified natural allergen. These differences mainly originate from certain post-
translational modifications which are not an integral part of the gene expression machinery 
of the heterologous host where the allergens are expressed (e.g., E.coli) or from incorrect 
3D folding of the artificial molecule (Pauli and Malling, 2010). 
Growing efforts in the molecular characterization of allergens and the development of 
innovative assay designs will permit medical experts to use recombinant allergen-based 
approaches for the diagnosis and treatment of allergic diseases in the future. In combination 
with established standards, the interpretation of these novel test formats should be guided 
by diagnostic decision trees and guidelines that could be proposed by international 
committees of allergy experts. Large-scale studies will reveal reactivity patterns that may 
help to improve the predictive value of allergy diagnosis by using component diagnostic 
signatures for in vitro testing, disease prevention in early life and monitoring of specific 
immunotherapies. Combined efforts in allergy research and clinical diagnosis will lead to a 
better understanding of the effectiveness of single allergen molecule-based approaches and 
will help to improve the treatment of allergic diseases significantly. 
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1.6. Allergy to banana and banana allergens 
 
Banana (Musa acuminata) is a very popular fruit worldwide. It is available year round and 
is very present in human nutrition. However, in 1991 symptoms of angioedema and 
anaphylactic shock caused by banana ingestion were described for the first time (M’Raihi 
et al., 1991). Allergic reactions to banana manifested in edema formation, collapse, 
urticaria, swelling of the hands, oral pruritus, rhinitis, cough, asthma and anaphylaxis. 
It was noticed that people allergic to bananas quite often had the same reaction after contact 
with pollen of other plants (Reindl et al., 2002; Grob et al., 2002) or latex products, and by 
using sera of allergic patients it was demonstrated that this is caused by cross-reactive IgE 
antibodies (Sanchez et al., 1999). In 1994 the term "latex-fruit syndrome" was established, 
which is based on the fact that 52% of patients allergic to latex are also sensitized to fruits, 
like avocado (36%), chestnut (36%), bananas (28%), kiwi (20%) and papaya (12%). 
(Lavaud et al., 1992; Anibarro et al., 1993; Blanco et al., 1994; Makinen-Kiljunen, 1994). 
Although many people think they are allergic to bananas, they actually have another form 
of intolerance to this fruit. Banana contains certain amines that cause digestive problems in 
people with a weak or sensitive digestive system. The enzyme diamine oxidase which 
participates in the digestion of these amines is not synthesized by some people and they are 
hence not able to break down the proteins that are found in bananas and experience 
digestive problems, symptoms that are often missinterpreted as a true allergic reaction to 
banana (Palacin et al., 2001). 
 
1.6.1. Banana allergens 
 
Banana belongs to the group of fruits with high water content, along with cherries, papaya, 
and avocado. It is therefore susceptible to fungal attack, so it is of no surprise that 
proteases, chitinases, and antifungal proteins are among the most dominant proteins found 
in this fruit. The mentioned proteins are actually associated with pathogenesis related 
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proteins (PR proteins) in plants whose expression is induced by pathogens, mechanical 
wounds or enviromental stress (Breiteneder, 2000). 
 
Familiar banana allergens are designated Mus a 1 to 5. Mus a 1 is a 14 kDa profilin 
showing an IgE-binding prevalence of 44% in 16 sera with suspected banana allergy and a 
high cross reactivity with its homologous allergens from other plant foods, latex and 
pollens. Mus a 2 corresponds to a 33 kDa class I chitinase harboring a hevein-like N-
terminal domain, and represents a major banana allergen in patients suffering latex-fruit 
syndrome. It displays very similar structural (i.e. amino acid sequence) and immunological 
properties to Pers a 1, its homologous class I chitinase and allergen from avocado fruit. 
Currently, three additional banana allergens have been added to the list: Mus a 3.0101, a 
non-specific lipid transfer protein (LTP), and Mus a 4.0101 and Mus a 5, corresponding to 
a thaumatin-like protein (TLP) and β-1,3-glucanase, respectively (Palacin et al., 2011). 
Banana endo-β-1,3-glucanase and thaumatin-like protein are  pathogenesis-related (PR) 
proteins (Barre et al., 2009). The glucanase is a 33 kDa protein belonging to the PR-2 plant 
protein family (Barre et al., 2009), whose putative role in the latex-fruit syndrome has been 
suggested, but not clearly demonstrated (Wagner et al., 2005). The PR-2 family also 
comprises well-known allergens from rubber latex, Hev b 2 (Heucas et al., 2001), and olive 
pollen, Ole e 9 (Yagami et al., 2002). Both are N-glycosylated glucanases (Yagami, 2002; 
Yagami et al., 1998), which have been proposed to be involved in latex- and/or pollen-plant 
food cross-reactivity (Yagami, 1998; Palomeras et al., 2005; Barber et al., 2008), and 
behave commonly as minor allergens, although sensitization to Ole e 9 significantly 
increases in geographical areas where olive pollen exposure is high (Leone et al., 2006). 
The 21 kDa banana TLP is the second PR protein (PR-5 family) targeted as a potential 
allergen (Breiteneder, 2004). Homologous allergenic proteins have been described in plant 
foods and pollens (Gavrović-Jankulović et al., 2002). Thus, Act d 2 from kiwifruit (Palacin 
et al., 2008), a food related to latex and banana allergy, has been recently identified as a 
major allergen in Spanish adults with kiwifruit allergy (Oberhuber et al., 2008). 
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Interestingly, the apple thaumatin-like allergen Mal d 2 is glycoprotein with complex 
asparagine-linked glycans (Palacin et al., 2008; Oberhuber et al., 2008; Breiteneder, 2000).  
 
1.6.2. β-1, 3-glucanase 
 
β- 1, 3-glucanase was designated as Mus a 5. In s study where sera from 51 banana allergic 
patients were examined, purified natural Mus a 5 reacted with serum IgE from 84% of sera 
(Grob et al., 2002). 
 
The biological role of this protein is the hydrolyses of 1,3-β-D-glycosidic bonds in 1,3-β-D-
glucans, such as laminarin and paramilon, and the degradation of glucans involved in the 
composition of hyphae filamentous fungi, and thus it has a protective role, and belongs to 
PR-2 proteins. The amount of β-1,3-glucanase in banana increases significantly during 
ripening (Breiteneder, 2000). 
The E.C. number of β-1,3-glucanase is 3.2.1.39. This enzyme is a homodimer that is stable  
at temperatures up to 70°C . The molecular weight of one subunit is 33.451 kDa (Heucas et 
al., 2001). Two Mus a 5 isoforms were determined by 2D immunoblot technique (pI 7.7 
and 8), and both isoforms have an identical N-terminal amino acid sequence of the first 10 
amino acids (Aleksic et al., 2012). Banana glucanase is made up of 312 amino acid residues 
and the amino acid sequence of this protein (without the signal sequence) is given in Figure 
5. 
 
Figure 5. Amino acid sequence of β-1, 3-glucanase from banana 
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This allergen is not yet fully characterized in terms of IgE binding epitopes and it is 
necessary to do its detailed characterization (Heucas et al., 2001). Its homolog is an 
important latex allergen β-1, 3-glucanase (Hev b 2) from Hevea brasilianis, a tropical tree 
used as the raw material for production of latex (Grob, 2002). In addition to homology with 
Hev b 2, banana β-1,3-glucanase shows significant homology with the Ole e 9 allergen 
from olive pollen  (Barre et al., 2009). 
The aim of this thesis was to produce recombinant β-1, 3-glucanase from banana denoted as 
rMus a 5 for the application in component resolved diagnosis of banana allergy. For this 
purpose, optimization of the recombinant protein production and detailed biochemical and 
immunochemical characterization was performed. 
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2. Results 
 
2.1. Cloning of recombinant β-1, 3-glucanase from banana  
 
Gene of β-1, 3-glucanase designed as Mus a 5 was isolated from total RNA of banana fruit 
by an RNeasy Plant Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer’s 
instructions. Complementary DNA (cDNA) was transcribed by a RevertAidTM First 
Strand cDNA synthesis kit (Fermentas UAB, Vilnius, Lithuania). For amplification of the 
mature gene of Mus a 5, sense and antisense – specific primers with EcoR I and Xho I 
restriction sites 5’-GAATTCATTGGTGTCTGCTACGG-3’ and 5’-
CTCGAGCTAAAAGCTTATTTGGTAGAC-3’ were used, respectively. The amplified 
Mus a 5-encoding fragment was cloned into a pGEX-4T vector, and the construct was 
verified by DNA sequencing. The cloning strategy was to produce recombinant Mus a 5 
(GenBank GQ268963) with glutathione-S-transferase as an expression tag on the N-
terminal. 
 
 
Figure 6. Agarose gel electrophoresis: L) Ladder 1 kb (Fermentas), 1) and 3) banana glucanase 
gene (1023 bp), 2) pGEX-4T. 
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The genes of banana glucanase (1023 bp) and pGEX-4T were digested with restriction 
enzymes XhoI and BamHI. After isolation form agarose gel the gene was ligated into the 
vector.   
 
 
Figure 7. Cloning strategy of Mus a 5 gene into the pGEX-4T vector. 
 
The cloning strategy introduced GST tag on the N-terminal of the GST-Mus a 5 construct 
(Figure 7). 
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2.2. Cell growth and induction of protein expression 
 
In order to optimize protein expression of a given construct, a time course analysis of the 
level of protein expression is recommended. Therefore, for the optimization of rGST-Mus a 
5 expression upon induction of protein synthesis, BL21 (DE3) cells were grown at different 
temperatures, i.e., 25, 30 and 37°C. Aliquots taken after 3, 6 and 12 h upon rGST-Mus a 5 
induction were analyzed by SDS-PAG electrophoresis. Densitometric comparison of the 
intensity of the rGST-Mus a 5 band with all other constitutively expressed proteins per 
lane, revealed that the highest yield of expression was obtained after 12 h of induction of 
protein synthesis under the all tested temperatures (Figure 8). For the  production of 
recombinant Mus a 5 inocula were prepared from transformed BL21 cells that were grown 
overnight at 37 °C in LB medium with antibiotics (100 mg L-1 ampicillin, 25 mg L-1 
chloramphenicol and 25 mg L-1 kanamycin). The culture (0.5 mL) was introduced into 10 
mL of LB medium containing the respective antibiotics. Once the absorbance (OD600) 
reached a value of 0.6 following an initial growth phase, protein expression was induced 
with 1 mM IPTG (Fermentas), and the cells were grown at 25, 30 or 37 °C. Following 
induction of protein expression, aliquots (1 mL) were taken after 3, 6 and 12 h. The band of 
about 60 kDa, representing rGST-Mus a 5, is predominant in all tested samples, except in 
the non-induced cells with the pGEX-4T-glucanase plasmid (Figure 8, lane 1) and after 3 h 
of induction of protein synthesis at 25 °C (Figure 8, lane 2). Taking into consideration the 
presence of other proteins in the cell lysates, the optimal conditions for the protein 
expression and further downstream purification was protein synthesis for 12 h at 25 °C. 
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Figure 8. Time course of recombinant Mus a 5 expression at 25, 30 and 37 °C. Expression of 
recombinant Mus a 5 was induced with 1 mM IPTG. Aliquots were removed at the times indicated. 
Proteins were visualized by Coomassie brilliant blue staining; line 1: control, MM: molecular 
markers. 
 
2.3. Activity of rGST under denaturing conditions 
 
Since a large amount of rGST-Mus a 5 was detected in inclusion bodies we tried to design 
an enzyme assay for monitoring expression and solubility of GST fusion protein targeted to 
inclusion bodies. To measure enzyme activity of the isolated rGST-Mus a 5 under 
denaturing conditions urea was used as a chaotropic agent. Enzyme activity was evaluated 
after 30 min of incubation in increasing concentrations of urea (0-8 M). It was shown that 
rGST retains almost 85% of activity after 30 min of incubation in buffer containing 2 M 
urea, while 50% of its activity was detected following incubation in 5 M urea, indicating 
that it could be possible to detect enzyme activity of GST-tagged proteins in denaturing 
conditions of 4 M urea. 
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In order to assess the possible application of rGST activity assay for monitoring the 
expression and solubility, the activity of GST expressed in bacterial cell lysate was 
measured. Aliquots taken during different time intervals of bacterial cell growth and IPTG-
induced protein expression were centrifuged and the cell pellet was suspended either in 
buffer A (0 M urea, non-denaturing conditions) or buffer B (4 M urea, denaturing 
conditions). Following cell lysis of the samples (three freeze-thaw cycle following 
sonication) and centrifugation, GST activity was detected in the cell lysates under 
denaturing conditions. GST activity was more than two-fold higher in the samples obtained 
following extraction under denaturing conditions (4 M urea). The higher activity detected 
under denaturing conditions suggest that inclusion bodies had been formed and 
subsequently solubilized in 4 M urea. This enables detection of rGST both in soluble form 
and in the solubilized inclusion bodies (Figure 9). 
 
 
 
Figure 9. GST activity in bacterial cell lysate detected following extraction using buffer A with 0 M 
urea (—■—) and buffer B with 4M urea (- -□- -). Filled circles represent GST activity detected in 
control cells (activity was identical under native and denaturing conditions). Shaded area 
represents optical density at 600 nm during cell growth. 
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2.3.1. Monitoring rGST-Mus a 5 expression in inclusion bodies using GST 
assay 
 
Aliquots taken during different time intervals of bacterial cell growth and IPTG-induced 
protein expression were centrifuged and the cell pellet was suspended either in buffer A 
(0M urea, non-denaturing conditions) or buffer B (4M urea, denaturing conditions). 
Following cell lysis of the samples (three freeze-thaw cycles following sonication) and 
centrifugation, GST activity was detected in the cell lysates under non-denaturing and 
under denaturing conditions.  
 
 
 
Figure 10. Detection of GST activity of GST-Mus a 5 in bacterial cell lysates prepared using buffer 
A with 0M urea (—■—) and buffer B with 4M urea (- -□- -). Filled circles represent GST activity 
detected in control cells (activities were same under native and denaturing conditions). 
 
Under non-denaturing conditions, GST activity of the constructs was almost undetectable, 
implying aggregation of expressed recombinant protein in inclusion bodies under employed 
experimental conditions. In the following step, the pellets were solubilized in 4M urea and 
GST activity was detected in the GST assay with 2M urea. Protein accumulation in 
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inclusion bodies was confirmed by GST affinity purification protocol for rGST-Mus a 5 
(Figure 10). 
 
2.4. Isolation of in vitro refolded recombinant GST-Mus a 5 
 
As the cloning strategy adds GST as a tag to the recombinant protein, the purification 
strategy was to employ glutathione (GSH) affinity chromatography for protein isolation.  
Recombinant GST-Mus a 5 was isolated from BL21 cells by glutathione affinity 
chromatography. Prior to affinity purification, the cells were harvested by centrifugation 
and after resuspension were lysed with lysozyme. Benzonase was employed to reduce the 
viscosity of the cell lysate caused by nucleic acids. By SDS-PAG electrophoresis and GST 
enzyme assay it has been revealed that the majority of produced rGST-Mus a 5 was 
accumulated in the insoluble fraction of the cell lysate, and its solubilization was achieved 
with 4 M urea. Prior to separation, denatured rGST-Mus a 5 was refolded by rapid batch 
dilution.  
 
The homogeneity of the isolated rGST-Mus a 5 was assessed by SDS-PAG electrophoresis, 
revealing a protein band of about 60 kDa (Figure 11). The yield of the purified rGST-Mus a 
5 was about 35 mg L–1 of LB, as calculated using the molar extinction coefficient for rGST-
Mus a 5 (1.434). The extinction coefficient for the GST-Mus a 5 construct was calculated 
from the primary structure by ProtParam (http://expasy.org/cgi-bin/protparam).  
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Figure 11. SDS-PAG electrophoresis of purified rGST-Mus a 5 produced in E. coli: 1) fraction of 
solubilized rGST-Mus a 5, 2) rGST-Mus a 5 eluted from the affinity matrix, MM) molecular 
markers. 
 
2.5. Optimization of the isolation of recombinant GST-Mus a 5 
 
Affinity chromatography is one of the most diverse and powerful chromatographic methods 
for purification of a specific molecule or a group of molecules from complex mixtures. It is 
based on highly specific biological interactions between two molecules, such as interactions 
between enzyme and substrate, receptor and ligand, or antibody and antigen. These 
interactions, which are typically reversible, are used for purification by placing one of the 
interacting molecules, referred to as affinity ligand, onto a solid matrix to create a 
stationary phase while the target molecule is in the mobile phase (Urh, 2009). Glutathion- 
based affinity chromatography is very often employed method for purification recombinant 
GST tagged proteins. This method was employed as a first step in the purification of the 
recombinant GST-Mus a 5 (Figure 12). 
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 Ion exchange is probably the most frequently used chromatographic technique for the 
separation and purification of proteins, polypeptides, nucleic acids, polynucleotides, and 
other charged biomolecules (Bonnerjera, 1986). 
  
  Anion exchanger                   Functional group 
 
Diethylaminoethyl (DEAE)    -O-CH2-CH2-N+H(CH2CH3)2 
 
The reasons for the success of ion exchange are its widespread applicability, its high 
resolving power, its high capacity, and the simplicity and controllability of the method. 
Separation in ion exchange chromatography depends upon the reversible adsorption of 
charged solute molecules to immobilized ion exchange groups of opposite charge. Ion 
exchange separations may be carried out in a column, by a batch procedure or by expanded 
bed adsorption. Purification protocol for GST-Mus a 5 included separation onto an anion 
exchanger diethylaminoethyl (structure of DEAE functional group is given above). 
 
Reversed Phase Chromatography (RPC) is a chromatographic method in which the 
adsorption of hydrophobic molecules onto a hydrophobic solid support occurs in a polar 
mobile phase. Decreasing the mobile phase polarity by adding more organic solvent 
reduces the hydrophobic interaction between the solute and the solid support resulting in 
desorption. The more hydrophobic the molecule the more time it will spend on the solid 
support and the higher the concentration of organic solvent is required to promote de-
sorption. Reversed phase chromatography was the last step in the purification protocol of 
GST-Mus a 5. 
 
After overnight protein expression at 25 °C, BL21 cells were harvested by centrifugation 
and were re-suspended in ice-cold distilled water (v:v, 1:4). Protein extraction was achieved 
by sonication, and after centrifugation supernatant was separated onto GST-Bind resin 
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(Novagen). Details on the experimental work are given in the Experimental part of this 
thesis.  
    
 
 
                                                                                             
 
 
 
 
 
 
 
 
 
                                                                                                                           
 
 
 
 
  
 
 
                        
 
 
 
 
 
Figure 12. Scheme of the GST-Mus a 5 purification. 
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Elution of the bound proteins was achieved with GSH, which were afterward separated 
onto an ion exchange column (Hi Trap DEAE FF, Pharmacia). The final purification step 
was reversed phase chromatography (Supelco C5, Sigma Aldrich). Recombinant GST-Mus 
a 5 was eluted at 80 % of Solution B (retention time 15.05 min). All purification steps were 
analyzed by SDS-PAGE. 
 
 
 
Figure 13. Chromatogram obtained after purification of GST-Mus a 5 onto reversed phase 
chromatography column (Supelco 5). 
 
By optimizing the elution gradient GST-Mus a 5 was purified by reversed phase 
chromatography. Under the employed experimental conditions retention time for GST-Mus 
a 5 elution was 15 min. 
 
By a combination of affinity, ion exchange and reversed phase chromatography GST-Mus a 
5 was isolated as a single protein band in reduced SDS-PAGE of about 60 kDa (Figure 14) 
with a yield of 10 mg mL-1.  
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Figure 14. SDS-PAGE analysis of the purification protocol employed for GST-Mus a 5: M) 
molecular markers, 1) non-induced cells, 2) IPTG induced cells, 3) bound proteins eluted from the 
affinity column, 4) bound proteins eluted from ion-exchange column, 5) GST-Mus a 5 eluted from 
RP column.   
 
2.6. Structural characterization of recombinant GST-Mus a 5 
 
For the structural characterization of GST-Mus a 5 microsequencing was performed. The 
microsequencing (automated Edman degradation) is a method of sequencing amino acids in 
either a peptide or a protein. Phenylisothiocyanate is reacted with an uncharged N-terminal 
amino group, under mildly alkaline conditions, to form a cleavable derivative of N-terminal 
amino acid. Then, after consecutive transformations the more stable phenylthiohydantoin 
(PTH) amino acid derivative is formed. The PTH amino acid derivative can be identified by 
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using chromatography or electrophoresis. The procedure can then be repeated again to 
identify the next amino acid. A major drawback to this technique is that the peptides being 
sequenced in such manner cannot have more than 50 to 60 residues. 
 
For Edman degradation the proteins may be provided in either solution or as a stained band 
of PVDF membrane derived from an electroblot. At least 10 pmoles of protein are 
necessary to run 10-15 cycles. For extended number of cycles it is recommend 100 pmoles 
of homogeneous protein. Sequencing of short peptides usually require 100-1000 pmoles. 
For the microsequencing GST-Mus a 5 was electrotransferred onto a PVDF membrane after 
2D PAGE. The identity of the construct was confirmed as the first five amino acids 
determined by Edman degradation (MSPIL). 
 
2.7. Evaluation of immunological reactivity of GST-Mus a 5  
 
For the employment in the component-resolved allergy diagnosis a candidate allergen 
beside structural features should share also immunological reactivity with its natural 
counterpart. In this regard various immunological assays find application in the 
characterization of recombinant allergens. Several methods have been extensively 
employed for the testing of recombinant allergen immunoreactivity such as evaluation of 
IgG and IgE reactivity in qualitative, semiquantitative and quantitative assays. 
 
2.7.1. IgG reactivity in immunoblot 
 
For the evaluation of IgG reactivity of GST-Mus a 5 immunoblot and immunoblot 
inhibition assays were employed. IgE reactivity of GST-Mus a 5 was evaluated by ELISA. 
Immunoblot alternatively, Western blot, or dot-blot, is an analytical technique used to 
detect specific proteins in a patients’ sample. The proteins to be analyzed are dispensed 
onto a membrane (usually nitrocellulose, nylon or PVDF), where they are probed by the 
antibodies of the patient. A simple secondary antibody conjugated to a reporter dye forms 
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the basis of the color reaction which can be read by eye (qualitative) or instrument 
(qualitative and quantitative). In the field of diagnostics their use is widespread as a 
screening tool where a patient can be profiled against multiple markers simultaneously.  
Western Blotting (also called immunoblot) is a technique used for analysis of individual 
proteins in a protein mixture (e.g. a cell lysate). The protein mixture is applied to a gel 
electrophoresis (SDS-PAGE, native PAGE, isoelectric focusing, 2D gel electrophoresis, 
etc.) to sort the proteins by size, charge, or other differences in individual protein bands. 
The separated protein bands are then transferred to a membrane (e.g. nitrocellulose, nylon 
or PVDF), by process which is called blotting. The proteins adhere to the membrane in the 
same pattern as they have been separated on the gel. The proteins on this immunoblot are 
then accessible for antibody binding for detection. 
 
To analyze IgG reactivity of GST-Mus a 5, rabbit polyclonal antiserum produced against 
natural banana glucanase was employed. GST-Mus a 5 was separated according to pI by 
isoelectric focusing (first dimension), and thereafter was separated according to the 
molecular mass on a SDS-PAGE (second dimension). Upon equilibration of the SDS-PA 
gel the protein was electrotransferred onto PVDF membrane for the detection of IgG 
reactivity. 
 
 
Figure 15. 2-D immunoblot analysis of GST-Mus a 5: isoelectric focusing was performed under 
native conditions and SDS-PAGE was performed under reduced conditions. Anti-Mus a 5 
antibodies were employed for detection of GST-Mus a 5. 
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In 2-D immunoblot GST-Mus a 5 revealed one broad spot of about 60 kDa with pI about 
5.7. By using anti-Mus a 5 rabbit antibodies, IgG reactivity of recombinant protein was 
shown in 2-D immunoblot (Figure 15) indicating presence of immunoreactive epitopes on 
the recombinant protein. 
 
2.7.2. IgE reactivity of rGST-Mus a 5 in dot blot 
 
The IgE reactivity of the rGST-Mus a 5 was examined by dot blot analysis using the sera of 
six banana allergic patients. To evaluate the IgE reactivity of the fusion tag, recombinant 
GST was also tested as a control. IgE reactivity was detected only for the rGST-Mus a 5, 
(Figure 16) while no IgE binding was found for GST. Although the correct protein folding 
should be confirmed by a thorough structural characterization, the IgE reactivity of the 
rGST-Mus a 5 suggests that this protein could find application as a diagnostic reagent in 
banana allergy. 
 
 
 
Figure 16. IgE reactivity of rGST-Mus a 5: 1-6) individual sera from banana allergic persons, 7) 
pool of sera from 3 healthy individuals, ca) control of secondary antibody, IgE reactivity of rGST: 8 
– pool of sera from 6 banana allergic persons, 9 – pool of sera from 3 healthy individuals and cb – 
control of secondary antibody. 
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 3. Discussion 
 
In this study the molecular and immunochemical characterization of recombinantly 
produced Mus a 5 allergen from banana fruit was performed. The production of 
recombinant proteins in a well-characterized form has become an important issue in the 
pharmaceutical industry (Walsh, 2010). One of the main advantages of recombinant 
proteins is that they can be fully characterized in terms of their physical, chemical, and 
immunologic properties and presented as chemically defined entities with all batches 
deriving from 1 master cell bank (Cromwell et al., 2011). Therefore, preparations for 
specific immunotherapy and diagnosis can be formulated with consistent high 
pharmaceutical quality to meet specifications that cannot be achieved with products based 
on extracts of natural source materials.  
  
Among epitope peptides and proteins developed for recombinant protein over-production, 
besides His tag, GST is very often employed as a fusion partner. Recombinant fusion 
proteins containing the complete amino acid sequence of GST exhibit a functional GST 
enzymatic activity. In addition to improving solubility, GST allows detection of the 
expressed recombinant protein using enzyme assays and GST-specific antibodies, and also 
facilitates recombinant protein purification (McTigue et al., 1995). Although most GST 
fusion proteins are expected to be soluble, many of them, even relatively small ones (40-50 
kDa), are partially or completely insoluble following lysis of prokaryotic cells (Frangioni 
and Neel, 1993; Hansen and Eriksen, 2007). To be able to detect accumulation of rGST-
Mus a 5 in inclusion bodies a colorimetric GST activity assay under denaturating (protein 
solubilization in 4 M urea) conditions has been employed in this study. By monitoring GST 
activity, expression and accumulation of GST-Mus a 5 in inclusion bodies was detected in a 
rapid, sensitive, cost effective and easy to perform manner. Compared to immunoassays 
that are based on quantitative detection of total GST, enzyme assays measure functional 
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GST activity, and therefore, are more reliable for downstream protein purification. 
However, the limit of the employment of enzyme assay is that it only confirms correct 
protein folding of recombinant GST enzyme, but it does not imply correct folding and 
hence biological activity of the protein of interest. Urea is usually used as a weaker and less 
expensive denaturant in comparison to guanidin chloride. The GST activity assay 
performed under denaturing conditions has the potential to be employed as a rapid 
screening method for determining the approximate expression levels of GST fused proteins 
targeted to inclusion bodies which can be solubilized in lower chaotrope concentrations (up 
to 4M urea) and therefore facilitate the subsequent refolding steps of these proteins.  
 
Several recombinant food allergens have been produced as GST tagged proteins, such as 
tropomyosins from crab (Cha f 1), lobsters (Hom a 1, Pan s 1) and shrimp (Met e 1), but 
also 2S albumin seed storage protein from walnut (Jug r 1) (Lorenz et al, 2001). In this 
study rMus a 5 was produced as a recombinant GST-tagged protein in E. coli.  
Recombinant Mus a 5 obtained from the bacterial cell lysate was purified under native 
conditions by affinity, ion exchange and reversed phase chromatography. Although protein 
expression was optimized, relatively high amount of recombinant protein was entrapped in 
inclusion bodies. The N-terminal sequence of the first five amino acids of purified protein 
was confirmed by Edman degradation. The protein revealed one spot (60 kDa, pI 5.7) 
which was immunoreactive with rabbit anti-Mus a 5 polyclonal antibodies in 2-D 
immunoblot. By using blood samples of latex allergic persons and the set of synthetic 15-
mer peptides Barre et al., identified five IgE reactive epitopes along the entire amino acid 
sequence of Mus a 5. The first IgE reactive epitope was localized fifteen amino acids from 
the N terminus. As it was shown for GST-tagged tropomyosins (Lorenz, 2001) it seems that 
IgE reactivity of rMus a 5 was not affected by GST tag, settled on the N terminus. 
However, epitope mapping with a representative pool of banana allergic patient’s sera 
should be performed to assess linear and eventual conformational IgE epitopes on Mus a 5.  
Various endogenous and exogenous factors influence protein expression pattern in banana 
fruit (Peumans et al., 2002, Choudhury et al., 2009, Choudhury et al., 2010). Comparative 
analysis revealed differences in β-1,3 glucanase gene expression, glucanase activity and 
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fruit pulp softening rates in three naturally occurring cultivars. Also, proteins from natural 
biological material often exhibit microheterogeneity. Natural Mus a 5 revealed several pI 
isoforms in range 7.7 to 8.0 (Aleksic et al., 2012). Recombinant Mus a 5 is a homogenous 
protein species and its expression yield in the prokaryotic expression system was about 10 
mg per liter of the cell culture.  
 
Current in vitro diagnosis of food allergy is limited because of inconsistent quality of plant-
food allergen extracts. Considerable knowledge obtained on food allergen characteristics 
can facilitate replacement of non-standardized food allergen extracts with component-
resolved diagnostic approach. Although it is tested in a rather small group of banana 
allergic persons, recombinant Mus a 5 showed IgE reactivity comparable to nMus a 5. 
Therefore, further testing of clinical reactivity of rMus a 5 can approve its application in the 
component-resolved diagnosis of banana allergy. 
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4. Experimental work 
 
 
4.1. Growth Media and Antibiotics   
 
In this work growth media for growth of strains of Escherichia coli for multiplication of 
vectors and expression of target proteins were Luria-Bertani (LB), and Luria-Agar (LA). 
 
4.1.1. Luria-Bertani (LB) medium 
 
LB medium    Per liter 
Tryptone (Torlak)   10 g 
Yeast extract      5 g 
NaCl       5 g 
1M NaOH      1 mL 
Distilled water#          up to   1000 mL 
 
# Distilled water was added up to 900 mL and the pH was adjusted to 7.5, after which water 
was added up to the 1 liter.  
 
In 0.5 liters of LM medium was prepared in a 1-liter flask and heated with stirring until 
chemicals were dissolved. The medium was poured into bottles with loosened caps and 
autoclaved 20 min at 15 lb/in2. Before the addition of antibiotics the suspension was cooled 
to ∼50 ºC, and the caps were tightened after the bottles cooled down to <40 ºC. The 
medium prepared in such a manner can be stored indefinitely at room temperature. 
Amplicilin was added to the final concentration of 100 µg mL-1 of LB. 
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4.1.2. Luria-Bertani (LB) agar 
 
LB agar    Per liter 
Tryptone (Torlak)   10 g 
Yeast extract      5 g 
NaCl       5 g 
1M NaOH      1 mL 
Agar (Torlak)    15 g 
Distilled water  up to 1000 mL 
 
The listed chemicals were mixed by stirring and autoclaved for 25 min. The medium was 
cooled down to ∼50 ºC before addition of antibiotics (ampicilin, 100 µg mL-1) with stirring. 
About 40 mL of liquid LB agar was poured per 10/cm plate (∼25 to 30 plates per liter). The 
plates were left until agar solidifies with the lids off for about 20-30 min at room 
temperature. Wrapped dry plates were stored at 4 ºC. 
 
4.2. Amplification of glucanase gene by PCR 
 
The glucanase gene was amplified by PCR with primers carrying restriction sites for EcoRI 
and Xho I. 
  
4.2.1. PCR reaction 
 
The primers used for gene amplification were as follows: 
 
Forward primer: 5’- GAATTCATTGGTGTCTGCTACGG -3’  
Revere primer: 5’- CTCGAGCTAAAAGCTTATTTGGTAGAC -3’ 
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 The PCR reaction was set up as follows: 
 
Buffer 10x    10 µL 
10 mM dNTPs     1.0 µL 
10 mM forward primer    1.0 µL 
10 mM reveres primer    1.0 µL 
Dream Taq Polymerase       0.5 µL 
Template DNA     1.0 µL 
dH2O                 85.5 µL 
Total volume                     100.0 µL 
 
Water was added first, than the buffer, nucleotides (dNTP), primers, template DNA, DNA 
polymerase, and at the end oil to prevent evatoration. 
 
PCR was performed under the following conditions: 
 
Step  Temperature (ºC) Time (sec) No. of cycles 
Initial denaturation 94 180           
 
Denaturation  94 45  
Annealing  63 45   30 
Extension  72 45  
Final elongation 72 600  
 
To analyze the reaction mixture after PCR samples were analyzed by agarose gel 
electrophoresis. 
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4.2.2. Purification of PCR product  
 
Purification of the PCR product was performed by GeneJETTM PCR purification kit 
(Fermentas).  
 
Reagents 
Buffer PBI    450 µL 
Buffer PE    750 µL 
PCR reaction mixture     90 µL 
dH2O     100 µL 
  
Procedure 
1. Buffer PB1 (450 µL) was placed into QIA tube and 90 µL of sample was mixed and 
centrifuged at 10 000 rpm for 1 min. 
2. Buffer PE (750 µL) was added to the column and the QIA tube was centrifuged at 13 000 
rpm for 1 min. After centrifugation the flow through solution was discarded and the 
columns were centrifuged at 13 000 rpm for 1 min to dry.  
3. To elute the DNA distilled water (40 µL) was added to the column and incubated for 1 
min and afterwards the column was centrifuged at 13 000 rpm for 1 min.  
4. Eluted samples were collected in sterilized tubes. The purified PCR products were used 
for further experiments. 
 
4.3. Cloning of banana glucanase gene into pGEX-4T vector  
 
4.3.1. Agarose gel electrophoresis 
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1. Materials and solutions 
1. TBE buffer, 10X concentrated 
Tris base [tris(hydroxymethyl)aminomethane]  108 g 
Boric acid               55 g 
EDTA, disodium salt          7.5 g 
deionized water   up to      1000 mL 
 
2. Agarose gel (1%) 
Agarose (TopVisionTM LEGQ Agarose, Fermentas) 1g 
TBE buffer       99 mL 
 
For the preparation of agarose gel 1 g of agarose is mixed with 99 mL of TBE buffer into 
the glass flack. The suspension is heated until it dissolves, and boils for additional 2 min. 
 
3. Orange loading dye (Fermentas) 10 µL loading buffer 
4. DNA samples 
5. DNA molecular weighs markers (ladder) 
6. Ethidium bromide (10 mg mL-1) 
7. Water bath 
8. Horizontal gel electrophoresis apparatus 
9. Gel casting platform 
10. Gel combs (slot former) 
11. DC power supply 
 
Procedure 
1. Add electrophoresis-grade agarose to 1 × TBE electrophoresis buffer. Melt in a 
microwave oven or autoclave, mix thoroughly, and cool to 55 °C. Pour liquid agarose 
solution into a sealed gel casting platform and insert comb, ensuring that there are no 
bubbles. Allow gel to harden. 
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2. Remove comb taking care not to tear the sample wells. Place the gel with the platform in 
tank. Add electrophoresis buffer to cover the gel ∼1 mm above surface, making sure no air 
is trapped in the wells.  
3. Add 10× loading buffer to DNA samples (final concentration 1×) and load samples with 
a micropipette. Also load DNA molecular weight markers (ladder) for comparison. 
4. Attach leads so that DNA migrates toward the anode or positive lead. Electrophoresis 
was run at 1 to 10 V cm-1 of gel. Monitor the progress of separation process by migration of 
dyes in the loading buffer. 
5. Turn off the power supply when bromphenolblue has migrated a distance judged 
sufficient for separation of the DNA fragments. 
6. Stain 10 to 20 min in solution of ethidium bromide. Visualize and photograph DNA by 
placing gel on a UV light source. 
DNA fragments of ∼0.5 to 25 kb are well resolved using this method. 
 
4.3.2. Digestion of PCR product and pGEX-4T expression vectors 
 
For the protein expression gene of glucanase has been cloned into expression vectors 
pGEX-4T. PCR product and pGEX-4T were cut with EcoRI and Xho I restriction enzymes 
for 1.5 hours at 37 °C. The samples were centrifuged for 20 sec. at 13 000 rpm and 
analyzed by agarose gel electrophoresis. 
 
Reaction mixture  pGEX-4T PCR product 
10× Tango buffer    5 µL      5 µL 
Plasmid   30 µL  30 µL 
EcoRI        2 µL      2 µL 
Xho I      2 µL     2 µL  
dH2O        6 µL      6 µL 
Incubation   1.5 h, 37 ºC   1.5 h, 37 ºC 
Total volume              50.0 µL             50.0 µL 
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After digestion the banana glucanase gene and pGEX-4T were isolated form agarose gel. 
For the cloning of the glucanase into expression vector ligation mixture was prepared. 
 
4.3.3. Ligation of banana glucanase into pGEX-4T 
 
Ligation of the glucanase gene into pGEX-4T was performed under following conditions: 
 
10 × Ligation buffer   1.0 µL 
Insert     5.0 µL 
Plasmid    2.5 µL 
T4 DNA ligase (Fermentas)  0.5 µL 
dH2O     1.0 µL 
Total volume             10.0 µL 
Incubation        overnight, 16 ºC 
 
4.3.4. Transformation of DH5α cells 
 
Procedure 
DH5α chemically competent cells, prepared by employing CaCl2, were used for 
transformation with the ligation mixture of pGEX-4T with ligated PCR product. 
1. The ligation mixture (10 µL) was added to the chemically competent DH5α cells (100 
µL), and the mixture was incubated on ice for 10 min, than on 42 ºC for 42 sec., on ice for 
5 min, and upon addition of 0.5 mL of LB into the tube was incubated for 1h at 37 ºC with 
agitation (200 rpm). 
2. DH5α cells were transferred onto two LB agar plates containing antibiotic ampicilin 
(100 µg mL-1) and were incubated overnight at 37 ºC.  
3. Five colonies were transferred from the agar plates to LB media. All work was done in 
sterile conditions. 
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4. In five tubes with LB media (10 mL), ampicillin (10 µL, conc. 100 mg mL-1) was added. 
Each tube was inoculated with one colony from the plate by micropitte and vortexed to mix 
the media and to resuspend the cells. The tubes were incubated overnight at 37 ºC with 
shaking. 
 
4.3.5. Isolation of plasmid from DH5α cells 
 
Colonies of DH5α cells transformed with pGEX-4T-glucanase were used for isolation of 
these plasmids. One mL of each sample was transferred to eppi tubes and centrifuged for 1 
min at 13 000 rpm. Supernatants were discarded and an additional 1 mL of the samples 
were transferred into their respective tubes and centrifuged for 1 min at 13 000 rpm. The 
supernatants were discarded and the remaining pellets were used for plasmid purification. 
 
Plasmid purification was done according to the following procedure: 
 
1. The cell pellets were resuspended in 250 µL of the resuspention solution and vortexed. 
2. Lysis solution (250 µL) was added and the tubes were inverted 4-6 times. 
3. The neutralisation solution (350 µL) was added and tubes were inverted 4-6 times. The 
tubes were centrifuged for 5 min. at 13 000 rpm. 
4. The supernatant was transferred to a blue column and centrifuged for 1 min at 13 000 
rpm. The flow through was discarded. 
5. Five hundred µL of wash solution was added and centrifuged for 1 min at 13 000 rpm.  
6. The flow through was discarded. The washing and centrifugation was done for 1 min at 
13 000 rpm.  
7. The column was transferred into a new tube, and 35 µL of distilled water was added to 
the column. The tube was incubated for 2 min, and afterward centrifuged for 2 min. 
8. Detection of plasmids was done by agarose gel electrophoresis (2.5 µL of sample with 1 
µL of dye).  
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After UV light analysis of the agarose gel, positive clones of pGEX-4T-glucanase were 
identified. 
 
4.3.6. Digestion of pGEX-glucanase vector 
 
From positive clones the pGEX-4T-glucanase vector was isolated and digested with 
restriction enzymes XhoI and EcoRI. For this purpose large scale purification of the vector 
was performed. 
 
Reaction mixture 
10× Tango Buffer     5.0 µL 
XhoI       2.0 µL 
EcoRI       2.0 µL 
Vector     37.0 µL 
dH2O       6.0 µL 
Total volume    50.0 µL 
 
All components were mixed at 37 ºC for two hours and afterwards the temperature was 
increased to 80 ºC, for 20 min to inactivate the restriction enzymes. The samples were 
centrifuged for 20 sec. at 10 000 rpm and thereafter were analyzed by agarose gel 
electrophoresis. 
 
4.3.7. Transformation of BL21(DE3) cells with the pGEX-glucanase 
 
BL21 (DE3) cells were transformed with the pGEX-glucanase. For transformation cells 
were incubated with the vector for 10 min on ice. Thereafter, 0.5 mL of LB was added into 
the tube, which was then incubated in a water bath at 42 ºC for 1 min, and then at 37 ºC for 
60 min. 
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BL21 cells (0.15 mL) were spread per plate and were incubated overnight at 37 ºC. Three 
colonies from each plate were transferred into separate tubes containing LB media grown 
overnight at 37 ºC. 
 
4.4. Induction of protein expression  
 
Inocula were prepared from transformed BL21 cells that were grown overnight at 37 ºC in 
LB medium with antibiotics. The culture (0.5 mL was introduced into 10 mL of LB 
medium containing respective antibiotics. Once absorbance (OD600) reached a value of 0.6 
following an initial growth phase, protein expression was induced with 1 mM IPTG 
(Fermentas), and cells were grown at 25 ºC, 30 ºC, and 37 ºC, respectively. Following 
induction of protein expression, aliquots (1 mL) were taken after 3h, 6h, and 12 h. 
 
4.5. Monitoring enzyme activity of GST and GST-Mus a 5 in the 
presence of urea 
 
To monitor GST and GST-Mus a 5 activity in the presence of urea, BL21 cells transformed 
with respective plasmids (pGEX-4T and pGEX-4T-Mus a 5) were grown in LB media at 37 
°C. Once optical density value of 0.4 was reached (OD600 0.4), 1 mM IPTG was added in 
order to induce protein expression. During the course of cell growth and protein expression 
induction, aliquots (1 mL) were taken and cells harvested by centrifugation (5 min at 
14,000 × g). The pellet was suspended either in buffer A (100 mM KH2PO4, pH 6.5, 100 
µL) or buffer B (100 mM KH2PO4, pH 6.5, containing 4 M urea, 100 µL). Following three 
freeze-thaw cycles, suspensions were sonicated in ice water bath (20 min at 20 rms). 
Insoluble cell debris was removed by centrifugation (15 min at 14000 × g) and clarified 
supernatant was used for the enzymatic assay. For detection of GST activity in cell lysates, 
samples (100 µL) were mixed with 100 mM GSH (2 µL) and 2.08 mM CDNB (98 µL). 
61 
 
Chemically-competent E. coli cell lysate was used as control. Calculated activities were 
adjusted for values obtained from non-enzymatic controls.  
 
4.6. Soduim dodecyl sulphate polyacrylamide gel electrophoresis 
(SDS-PAGE) 
 
Sample Buffer (5×) 
10% w/v SDS 
10 mM  Dithiothreitol, or beta-mercapto-ethanol 
20 % v/v  Glycerol 
0.2 M   Tris-HCl, pH 6.8 
0.05% w/v Bromophenolblue 
The protein sample was mixed with the sample buffer (4:1, v:v), and that boiled for 5 
minutes. 
 
Running Gel Solution (1×) 
For different applications desired percentage of acrylamide gel should is prepared. To make 
up thirty mL of running gel selection of one of the following protocols (percentages) was 
followed, and respective ingredients were mixed. After adding TEMED and APS solution   
quickly polymerized into a gel. 
         7%    10%    12%   15% 
H2O     15.3 mL 12.3 mL 10.2 mL 7.2 mL 
1.5 M Tris-HCl, pH 8.8    7.5 mL   7.5 mL             7.5 mL 7.5 mL 
20% (w/v) SDS     0.15 mL   0.15 mL   0.15 mL 0.15 mL 
Acrylamide/Bis-acrylamide    6.9 mL   9.9 mL 12.0 mL         15.0 mL 
(30%/0.8% w/v)      
10%(w/v) ammonium persulfate      
(APS)      0.15 mL  0.15 mL   0.15 mL 0.15 mL 
TEMED     0.02 mL  0.02 mL   0.02 mL 0.02 mL 
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Stacking Gel Solution (4% Acrylamide) 
H2O       3.075 mL 
0.5 M Tris-HCl, pH 6.8    1.25 mL 
20% (w/v) SDS     0.025 mL 
Acrylamide/Bis-acrylamide(30%/0.8% w/v)  0.67 mL 
10% (w/v) ammonium persulfate (APS)  0.025 mL 
TEMED      0.005 mL 
 
Electrophoresis  buffer, pH 8.3 
0.25 M Tris       3.0 g 
0.192 M Gly                14.4 g 
0.1% SDS       1.0 g 
Destilled water up to     1000 mL 
Staining solution for PAA gels  
0.1% CBB G ili R 250       0.5 g 
50 % methanol                          100.0 mL 
10% acetic acid        10.0 mL 
Destilled wated      up to  200.0 mL 
 
Fixing solution (50% methanol, 10% acetic acid) 
methanol      500 mL 
acetic acid       100 mL 
Destilled wated     up to  1000 mL 
 
Destaining solution (25 % methanol, 5 % acetic acid)  
methanol      250 mL 
acetic acid          50 mL 
Destilled water     up to 1000 ml 
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Running the gel 
The gel was clamped in and both buffer chambers were filled out with gel running buffer 
according to the instructions manual. The power leads were attached and the gel was run 
until the blue dye front reaches the bottom. The gel was removed from the power supply 
and processed further. Proteins were visualized by using Coomassie Brilliant Blue.  
 
4.7. Optimized protocol for isolation of the recombinant GST-
Mus a 5  
 
After growing overnight cells were harvested by centrifugation (3000 × 30 min at 4 oC), re-
suspended in ice-cold distilled water (1:4,v:v) and extracted by sonication (5×10 seconds at 
25 W, Branson sonifier 150, Branson Ultrasonics, Danbury, Connecticut). After 
centrifugation (3000 × g, 30 min) PBS (1.5 M) was added to the cell supernatant (1:10, 
v:v), and after additional centrifugation (13000 × 5 min) protein solution was applied onto 
GST-Bind resin (Novagen, Darmstadt, Germany). Elution of the bound proteins was 
achieved with 50 mM Tris-HCl, 10 mM GSH, pH 8,0. After dialysis against 20 mM Tris 
pH 8,3 the recombinant protein was purified by ion exchange (Hi Trap DEAE FF, GE 
Healthcare, Little Chalfont, UK) chromatography on Akta Purifier (GE Healthcare, Little 
Chalfont, UK). The final purification step was reversed phase chromatography (Supelco 
C5, Sigma Aldrich, St. Louis, Missouri). The column was equilibrated with solution A 
(0,1% TFA), and bound proteins were eluted with a gradient of 10 CV of solution B (0,1% 
TFA in 90% ACN). Recombinant glucanase was eluted at 80% of solution B (retention 
time 15.06 mL). Purification steps were analyzed by SDS-PAGE. 
 
4.8. N-terminal sequencing  
 
For N-terminal sequencing recombinant glucanase was resolved on SDS-PAGE and 
thereafter transferred by semidry blotting onto a PVDF membrane (Serva, Heidelberg, 
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Germany). The membrane was subsequently washed in double-distilled water, stained (0.1 
% Coomassie Blue, Serva, in 50% methanol), destained (50% methanol) and air-dried. The 
protein band was excised and microsequencing was kindly performed by Prof. Arnd 
Petersen, Borstel Research Center, Germany, by using a Procise protein sequence 
connected to an online PTH amino acids analyzer (PE Biosystems, Weiterstadt, Germany). 
 
4.9. Production of polyclonal antibodies 
 
For the production of the polyclonal antibodies to banana extract two rabbits were 
immunized according to the protocol described by Harlow and Lane. In brief, 0.25 mL of 
banana extract (0.5 mg mL-1) which was prepared according to Gavrović-Jankulović et al. 
(2008), was mixed with 0.25 mL CFA (complete Freunds adjuvant) for the first 
immunization. Every 15 days, for four months, the rabbits were boosted with a mixture of 
0.25 mL of the banana extract and 0.25 mL of IFA (incomplete Freunds adjuvant). Each 
rabbit was subcutaneously immunized with 0.5 mL of the emulsion. After four months, sera 
were collected and the antibodies were pooled and fractionated by ammonium sulfate (50% 
saturation). After dialysis against phosphate buffer saline (PBS) antibodies were aliquoted 
and stored in 20% glycerol at –20°C. 
 
Antibodies against natural banana glucanase were raised in rabbits according to Harboe and 
Ingild, 1983, and were kindly provided by Ivana Aleksic, from the Institute for Virology, 
Vaccine and Sera, Torlak, Serbia.  
 
4.10. Immunodetection  
 
4.10.1. Immunoblot 
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Tris buffer saline (TBS), pH 7.6 
30 mM Tris         3.63 g 
150 mM NaCl        9.0 g 
Destilled water              up to 1000 mL 
 
TTBS (0.1%) 
Tween 20      0.1 mL 
TBS                 99.9 mL 
 
Blocking solution (5%) 
skim milk       5 g 
TTBS      up to 100 mL 
 
Antibody dillution solution   
0.1% solution of skim milk in TTBS 
 
Buffer for alkaline phosphatase (AP) pH 9,6 
100 mM TRIS      1.2 g 
50 mM MgCl2 x5H2O              10.0 mg 
Destilled water      up to 100.0 mL 
* pH adjusted with 3M NaOH 
 
AP substrate prepatration 
Substrate 1    Substrate 2 
BCIP  50 mg   NBT  100 mg 
AP buffer  20 ml   AP buffer 300 ml 
 
Solutions of substrate 1 and substrate 2 are made before usage. One volume of substrate 1 
is mixed with 9 volumes of substrate 2 and filtred.  
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Protocol: 
• Destaining of a membrane in tTBS for10 min.  
• Blocking of the membrane with 5% skim milk (in tTBS-u) 1 h at RT with shaking. 
• Washing of the membrane with tTBS (3 × 10 min). 
• Incubation of the membrane with the primary antibodies for 2 to 4 h at RT with shaking. 
• Washing of the membrane with tTBS (3 × 10 min).  
• Incubation of the membrane with the secondary antibodies for 1 h at RT with shaking. 
• Washing of the membrane with tTBS (3 × 10 min). 
• Incubation of the membrane with the alkaline phosphatase labeled tertiary antiboy fod 1 h 
at RT, with shaking.  
• Washing of the membrane with tTBS (3 × 10 min). 
• Washing of the membrane with TBS (1 × 10 min). 
• Detection of antigen-antibody interactions with BCIP/NBT substrate for alkaline 
phosphatase.  
 
4.10.2. Dot blot and 2-D immunoblot 
 
Six sera from persons with positive clinical history to banana allergy and positive skin 
prick test to banana extract were used for the evaluation of IgE reactivity of rGST-Mus a 5 
in dot blot. A pool of three sera from persons without banana allergy was used as a control. 
Purified rGST-Mus a 5 (5 μg) was applied to a nitrocellulose membrane (NC) using 96-
well dot blot hybridization manifold (VWR, Vienna, Austria). To discriminate IgE 
reactivity of the GST tag from IgE reactivity of glucanase, rGST was applied onto the NC 
membrane as a control. 
 
Membranes were blocked using 30 mM Tris buffer saline (TBS) pH 7.4, containing 5% 
w/v skimmed milk for 1 h at RT. Membranes were incubated with the pooled sera in 1 % 
skimmed milk in TBS (dilution, 1:3, v:v) overnight at RT. Goat anti-human IgE (dilution 
1:10000, v:v) was used for detection of IgE binding. Alkaline phosphatase-labeled rabbit 
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antigoat IgE antibodies (dilution 1:30000, v:v, Sigma) were used as the tertiary antibody. 
IgE reactive spots were visualized with BCIP/NBT solution. 
 
For detection of IgG reactivity of rGST-Mus a 5, rabbit antibodies against banana extract, 
or anti-banana glucanase rabbit antibodies were employed. After blocking, the membrane 
was incubated with the primary antibodies (dilution 1:5000) for 2 h at room temperature. 
After three washings, the membrane was incubated with alkaline phosphatase anti-rabbit 
antibodies (dilution 1:30000, Sigma–Aldrich, Missouri, USA). 
 
For 2D-PAGE, recombinant glucanase (15 µg) was separated by isoelectric focusing (IEF) 
under native conditions, and subsequently, strip was transferred onto SDS-PA gel (4% 
stacking and 12% resolving gel). The pH gradient of the IEF gel was determined by reading 
pH of 10 mM KCl solution (1 mL) in which slices of the gel (0.5 × 1 cm) were suspended 
for 30 min. For immunoblot analysis, separated proteins were transferred onto a PVDF 
membrane (Serva, Heidelberg, Germany) under 1 mA cm-2 for 1 h. After blocking in 5% 
skim milk in TPBS (150 mM NaCl, 12 mM Na2HPO4, 3 mM KH2PO4, 0.3% BSA, 0.01% 
Tween 20, pH 7.4) of the membrane for two hours, recombinant glucanase was detected 
using anti-glucanase polyclonal rabbit antibodies (1:5000, v:v) in TPBS. Goat alkaline 
phosphatase-labeled anti-rabbit secondary antibodies (1:30 000, v:v, Millipore, Billerica, 
MA, USA) in TPBS, were used for antigen detection. Visualization of the reaction was 
achieved with 5-bromo-4-chloro-3-indolyl phosphate/4-nitroblue tetrazolium (BCIP/NBT, 
Sigma-Aldrich, St. Louis, USA).  
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